10-K 1 omi1231201410k.htm 10-K OMI 12 31 2014 10K

 
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
 
 
FORM 10-K 
 
 
 

x
Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the year ended December 31, 2014
 
¨
Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the transition period from                      to                     
Commission File Number 1-9810
  
 
 
 
OWENS & MINOR, INC.
(Exact name of registrant as specified in its charter)
 
 
 
 
Virginia
 
54-1701843
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification No.)
 
 
 
9120 Lockwood Boulevard, Mechanicsville, Virginia
 
23116
(Address of principal executive offices)
 
(Zip Code)
Registrant’s telephone number, including area code (804) 723-7000
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Name of each exchange on which registered
Common Stock, $2 par value
 
New York Stock Exchange
3.875% Senior Notes due 2021
 
Not Listed
4.375% Senior Notes due 2024
 
Not Listed
Securities registered pursuant to Section 12(g) of the Act: None
 
 
 
Indicate by check mark if the registrant is a well-known seasoned issuer (as defined in Rule 405 of the Securities Act).    Yes  x    No  ¨
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes  ¨    No  x
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x   No  ¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ¨ 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer
 
x
  
Accelerated filer
 
¨
 
 
 
 
Non-accelerated filer
 
¨
  
Smaller reporting company
 
¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x
The aggregate market value of Common Stock held by non-affiliates (based upon the closing sales price) was approximately $2,143,004,902 as of June 30, 2014.
The number of shares of the Company’s common stock outstanding as of February 13, 2015 was 63,059,770 shares.
Documents Incorporated by Reference
The proxy statement for the annual meeting of shareholders to be held on April 30, 2015, is incorporated by reference for Item 5 of Part II and Part III.
 
 
 


1


Form 10-K Table of Contents
 
 
 
 
 
Item No.
 
 
Page
 
 
 
 
 
 
 
1

 
1A.

 
1B.

 
2

 
3

 
 
 
 
 
 
 
 
4

 
Mine Safety Disclosures
5

 
6

 
7

 
7A.

 
8

 
9

 
9A.

 
9B.

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10

 
11

 
12

 
13

 
14

 
 
 
 
 
 
 
 
 
 
 
 
15

 
Corporate Officers can be found at the end of this Form 10-K.



Part I
 
Item 1. Business
General
Owens & Minor, Inc. and subsidiaries (we, us or our), a Fortune 500 company headquartered in Richmond, Virginia, is a leading healthcare logistics company that connects the world of medical products to the point of care. We provide vital supply chain assistance to the providers of healthcare services and the manufacturers of healthcare products, supplies and devices. With fully developed networks in the United States and Europe, we are equipped to serve a customer base ranging from hospitals, integrated healthcare systems, group purchasing organizations, and the U.S. federal government, to manufacturers of life-science and medical devices and supplies, including pharmaceuticals in Europe. The description of our business should be read in conjunction with the consolidated financial statements and supplementary data included in this Form 10-K.
Founded in 1882, Owens & Minor was incorporated in 1926 in Richmond, Virginia. We focus our operations on healthcare logistics services and provide our customers with a service portfolio that covers procurement, inventory management, delivery and sourcing of products for the healthcare market. Through organic growth and acquisitions over many years, we significantly expanded and strengthened our company, achieving national scale in the United States healthcare market.
On August 31, 2012, we acquired the Movianto Group (Movianto), an established European healthcare third-party logistics provider. As a result of the acquisition, we entered into third-party logistics services for the pharmaceutical, biotechnology and medical device industries in the European market, leveraging an existing platform that also expands our ability to serve our United States-based manufacturer customers on an international level.
On October 1, 2014, we completed the acquisition of Medical Action Industries Inc. (Medical Action), a leading producer of surgical kits and procedure trays for the healthcare market. On November 1, 2014, we acquired ArcRoyal, a privately held surgical kitting company based in Ireland (ArcRoyal). These acquisitions further expanded our capabilities to provide our provider and manufacturer customers a range of packaging services, including the ability to package instruments and supplies into sterilized custom procedure trays used in a variety of clinical procedures, such as cardiac and orthopedic procedures, and sterilized minor procedure kits and trays which are used in a wide variety of minor surgical and medical procedures, such as I.V. start kits and suture removal. This packaged approach enables healthcare providers to track and manage the supply chain for products, supplies and instruments used in clinical settings. The combined consideration for these two acquisitions was $261.6 million, net of cash acquired, and including debt assumed of $13.4 million (capitalized lease obligations). These acquisitions did not have a material effect on operational results for 2014.
Our Domestic segment includes all functions in the United States relating to our role as a healthcare logistics company providing distribution, packaging and logistics services to healthcare providers and manufacturers. The newly acquired Medical Action operations are part of the Domestic segment. Our International segment consists of Movianto and ArcRoyal. Financial information by segment and geographic area appears in Note 20, “Segment Information,” of the Notes to Consolidated Financial Statements included in this annual report.
The Domestic Segment
Healthcare product volumes in the United States are dependent on the rates of utilization of medical/surgical procedures by consumers, which are subject to fluctuation according to the condition of the domestic economy and other factors. Aside from consumer-driven activity, the healthcare industry is also experiencing growing demand for advanced logistics services from healthcare providers and manufacturers that are focused on achieving more efficient and cost-effective supply-chain operations.
In the United States, healthcare supply distributors contract with group purchasing organizations (GPOs) that negotiate distribution contracts on behalf of their healthcare provider members and also contract directly with healthcare providers and manufacturers for their services.

3


Healthcare providers are increasingly consolidating into larger, more sophisticated networks that are actively seeking reductions in the total cost of delivering healthcare products. These healthcare providers face complex financial challenges, including managing the cost of purchasing, receiving, storing and tracking supplies. Economic trends have also driven significant consolidation within the healthcare products distribution and logistics industry due to the competitive advantages enjoyed by larger organizations. Among these advantages are the ability to serve customers in widespread geographic locations, purchase inventory in large volume, develop more sophisticated technology platforms and decision-support systems and provide expertise to healthcare providers and manufacturers to help reduce supply chain costs.
We offer a comprehensive portfolio of products and services to healthcare providers and manufacturers in the United States. Our portfolio of medical and surgical supplies includes branded products purchased in large volume from manufacturers and our own proprietary private-label products, which are internally sourced through our sourcing capabilities abroad or through a select group of manufacturers. We store our products at our distribution centers and provide delivery of these products, along with related services, to healthcare providers around the nation. Our packaging capabilities offer the packaging of instruments and supplies into custom and minor procedure kits and trays which are assembled and delivered based on the specifications provided by the healthcare provider customer. For sterilized kits and trays, we utilize one or more third-party sterilization contractors.
Most supplies are delivered using a leased fleet and almost all of our delivery personnel are our teammates, ensuring a consistent level of performance and customer service. In situations where they are more cost-effective and timely, we use contract carriers and parcel delivery services. We customize product deliveries, whether the orders are “just-in-time,” “low-unit-of-measure,” pallets, or truckloads. We also customize delivery schedules according to customers’ needs to increase their efficiency in receiving and storing products. We have deployed low-unit-of-measure automated picking modules in our larger distribution centers to maximize efficiency, and our distribution center teammates use voice-pick technology to enhance speed and accuracy in performing certain warehousing processes.
We also offer additional services to healthcare providers including supplier management, analytics, inventory management, outsourced resource management, clinical supply management and business process consulting. These value-add services help providers improve their process for contracting with vendors, purchasing supplies and streamlining inventory. These services include our operating room-focused inventory management program that helps healthcare providers manage suture and endo-mechanical inventory, as well as our customizable surgical supply service that includes the packaging and delivery of surgical supplies in procedure-based totes to coincide with the healthcare providers' surgical schedule.
The majority of our distribution arrangements compensate us on a cost-plus percentage basis, under which a negotiated percentage mark-up is added to the contract cost agreed to by the customer and the supplier. We price our services for certain other arrangements under activity-based pricing models. In these cases, pricing depends upon the type, level and/or complexity of services that we provide to customers, and in some cases we do not take title to the product (although we maintain certain custodial risks). As a result, this fee-for-service pricing model aligns the fees we charge with the cost of the services provided, which is a component of selling, general and administrative expenses, rather than with the cost of the product, which is a component of cost of goods sold.
We offer a variety of programs and services dedicated to providing logistics and marketing solutions to our manufacturer customers as well. These programs and services are designed to help manufacturers increase market share, drive sales growth, and achieve operational efficiencies. Manufacturer programs are generally negotiated on an annual basis and provide for enhanced levels of support that are aligned with the manufacturer’s annual objectives and growth goals. We have contractual arrangements with manufacturers participating in these programs that provide performance-based incentives to us, as well as cash discounts for prompt payment. Program incentives can be earned on a monthly, quarterly or annual basis.
All of our distribution and logistics services utilize a common infrastructure of distribution centers, equipment, technology, and delivery methods (internal fleet, common carrier or parcel services). We operate a network of 42 distribution centers located throughout the continental United States, which are strategically located to efficiently serve our provider and manufacturer customers, and two packaging facilities for the production of custom and minor procedure kits and trays. A significant investment in information technology supports our business including warehouse management systems, customer service and ordering functions, demand forecasting programs, electronic commerce, data warehousing, decision support and supply-chain management. During 2014, we completed a three-year, $54 million investment in our information technology infrastructure in the United States designed to achieve operational and data-management efficiencies, improve customer service, and reduce increases in future operating expenses.

4


The International Segment
Our International segment represented 5.2% of our consolidated net revenues during 2014. The segment includes Movianto and ArcRoyal. Through Movianto, we provide contract logistics services to the pharmaceutical, biotechnology and healthcare industry, offering a broad range of supply chain logistics services to manufacturers. Our warehousing and transportation offerings include storage, controlled-substance handling, cold-chain, emergency and export delivery, inventory management and pick & pack services. Our other services include order-to-cash, re-labeling, kitting, customer service and returns management. Through our packaging operations, we offer custom procedure trays to manufacturers and healthcare provider customers throughout Europe.
Our International segment has a network of 26 logistics centers and one packaging facility in 12 European countries, including Belgium, Czech Republic, Denmark, France, Germany, Ireland, Netherlands, Portugal, Slovakia, Spain, Switzerland and the United Kingdom. To serve our clients, we use a fleet of leased and owned trucks, including cold-chain delivery trucks. The majority of our drivers are our International teammates, although contract carriers and parcel services are used in situations where they are more cost-effective and timely.
Client logistics contracts in our International segment are generally for three-year terms with rolling automatic one- year extension periods. The tendering or competitive bidding process typically takes 12 to 18 months from the initial client request for proposal until becoming operational. We offer significant flexibility to tailor contracts to specific client requirements, and benefit from the expansion of clients into additional European countries. Pricing may be activity-based, with fees determined by clients’ particular requirements for warehousing, handling and delivery services, or it may be based on buy-sell wholesaler arrangements for product distribution.
Our Customers
We currently provide distribution, outsourced resource management and/or consulting services to thousands of healthcare provider customers. These customers include multi-facility networks of healthcare providers offering a broad spectrum of healthcare services to a particular market or markets (IHNs) as well as smaller, independent hospitals in the United States. In addition to contracting with healthcare providers at the IHN level and through GPOs, we also contract with other types of healthcare providers including surgery centers, physicians’ practices and smaller networks of hospitals that have joined together to negotiate terms. We have contracts to provide distribution services to the members of a number of national GPOs, including Novation, LLC (Novation), MedAssets Inc. (MedAssets), Premier, Inc. (Premier) and HealthTrust Purchasing Group (HPG). In 2012 and 2013, we renewed the distribution agreements with all four GPOs to continue our status as an authorized distributor for their member healthcare providers and allow us to compete with other authorized distributors for the business of individual members. Below is a summary of these agreements:
GPO
 
Year of Renewal
 
Term
 
Sales to Members as a % of Consolidated Net Revenue in 2014
Novation
 
2012
 
  5 years*
 
32%
MedAssets
 
2013
 
3 years
 
25%
Premier
 
2013
 
  3 years*
 
24%
HPG
 
2013
 
5 years
 
11%
 
 
 
 
 
 
 
* Agreement also includes two one-year renewal options after the initial term
 
 
We have our own independent relationships with most of our hospital customers through separate contractual commitments that may or may not be based upon the terms of our agreement with the GPO. As a result, the termination or expiration of an agreement with a particular GPO would not necessarily mean that we would lose the members of such GPO as our customers.
Our supplier and manufacturer customers represent the largest and most influential healthcare manufacturers in the industry. We have long-term relationships with these important companies in the healthcare supply chain and have long provided traditional distribution services to them. We currently have relationships with approximately 1,300 of these supplier and manufacturer customers. In the Domestic segment, sales of products supplied by subsidiaries of Covidien Ltd. accounted for approximately 14% of our consolidated net revenue for 2014. Sales of products supplied by Johnson & Johnson Health Care Systems, Inc. were approximately 10% of our consolidated net revenue for 2014.

5


In Europe, we serve a diverse customer base of approximately 600 manufacturer clients, including pharmaceutical, biotechnology and medical device manufacturers.
Asset Management
In the healthcare supply distribution industry, a significant investment in inventory and accounts receivable is required to meet the rapid delivery requirements of customers and provide high-quality service. As a result, efficient asset management is essential to our profitability. We continually work to refine our processes to optimize inventory and collect accounts receivable.
Inventory
We are focused in our efforts to optimize inventory and continually consolidate products and collaborate with supply-chain partners on inventory productivity initiatives. When we convert large-scale, multi-state IHN customers to our distribution network, an additional investment in inventory in advance of expected sales is generally required. We actively monitor inventory for obsolescence and use inventory turnover and other operational metrics to measure our performance in managing inventory.
Accounts Receivable
In the normal course of business, we provide credit to our domestic and European customers and use credit management techniques to evaluate customers’ creditworthiness and facilitate collection. These techniques may include performing initial and ongoing credit evaluations of customers based primarily on financial information provided by them and from sources available to the general public. We also use third-party information from sources such as credit reporting agencies, banks and other credit references. We actively manage our accounts receivable to minimize credit risk, days sales outstanding (DSO) and accounts receivable carrying costs. Our ability to accurately invoice and ship product to customers enhances our collection results and drives our positive DSO performance. We also have arrangements with certain customers under which they make deposits on account, either because they do not meet our standards for creditworthiness or in order to obtain more favorable pricing.
Competition
The medical/surgical supply distribution and healthcare logistics industries are highly competitive in the United States and Europe. The U.S. sector includes Owens & Minor, Inc., as well as two major nationwide manufacturers who also provide distribution services, Cardinal Health, Inc. and privately-held Medline, Inc. In addition, we compete with a number of regional and local distributors and customer self-distribution models. Major logistics competitors serving healthcare manufacturers in the United States and in Europe include United Parcel Service, FedEx Corporation, Deutsche Post DHL and Alloga, as well as local competitors in specific countries.
Regulation
The medical/surgical supply distribution industry in the United States is subject to regulation by federal, state and local government agencies. Each of our distribution centers is licensed to distribute medical and surgical supplies, as well as certain pharmaceutical and related products, and each of our packaging facilities is licensed to perform kit assembly operations. We must comply with laws and regulations, including those governing operations, storage, transportation, safety and security standards for each of our distribution centers and packaging facilities, of the Food and Drug Administration, the Centers for Medicare and Medicaid Services, the Drug Enforcement Agency, the Department of Transportation, the Environmental Protection Agency, the Department of Homeland Security, the Occupational Safety and Health Administration, and state boards of pharmacy, or similar state licensing boards and regulatory agencies. We are also subject to various federal and state laws intended to protect the privacy of health or other personal information and to prevent healthcare fraud and abuse. We believe we are in material compliance with all statutes and regulations applicable to our operations, including the Healthcare Insurance Portability and Accountability Act of 1996 (HIPAA), Medicare and Medicaid, as well as applicable general employment and employee health and safety laws and regulations.

6


Our International business is subject to local, country and European-wide regulations, including those promulgated by the European Medicines Agency (EMA) and the Medical Devices Directive. In addition, quality requirements are imposed by healthcare industry manufacturers which audit our operations on a regular basis. Each of our logistics centers in Europe is licensed to distribute medicinal, medical and surgical supplies, as well as certain pharmaceutical and related products, according to the country-specific requirements. Our logistics centers in Europe are able to store ambient, cold chain or deep frozen products, are licensed to distribute narcotic products and pharmaceutical products included in clinical trials and are licensed for secondary packaging activities for medicinal products. Movianto is also ISO 9001:2008 certified across the entire enterprise. Our Ireland-based packaging facility is licensed to assemble kits and sell them in the markets we serve and operates in compliance with the requirements of ISO 9001:2008 and ISO/EU 13485:2012 standards. We believe we are in material compliance with all statutes and regulations, including Good Distribution Practices sponsored by the European Commission.
Employees
At the end of 2014, we employed approximately 5,700 full- and part-time teammates in the Domestic segment and 2,100 in the International segment. Most of our international teammates are covered by collective bargaining agreements. Ongoing teammate training is critical to performance and we use Owens & Minor University®, an in-house training facility, to offer classes in leadership, management development, finance, operations, safety and sales. We continue to have positive relationships with teammates and European works councils.
Available Information
We make our Forms 10-K, Forms 10-Q and Forms 8-K (and all amendments to these reports) available free of charge through the SEC Filings link in the Investor Relations content section on our website located at www.owens-minor.com as soon as reasonably practicable after they are filed with or furnished to the SEC. Information included on our website is not incorporated by reference into this Annual Report on Form 10-K.
You may read and copy any materials we file with the SEC at the SEC’s Public Reference Room at 100 F Street, NE, Washington, DC 20549. You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC also maintains an Internet site that contains reports, proxy and information statements, and other information regarding the company (http://www.sec.gov).

Additionally, we have adopted a written Code of Honor that applies to all of our directors, officers and teammates, including our principal executive officer and senior financial officers. This Code of Honor (including any amendments to or waivers of a provision thereof) and our Corporate Governance Guidelines are available on our website at www.owens-minor.com.

Item 1A. Risk Factors
Set forth below are certain risk factors that we currently believe could materially and adversely affect our business, financial condition and prospects. These risk factors are in addition to those mentioned in other parts of this report and are not all of the risks that we face. We could also be affected by risks that we currently are not aware of or that we currently do not consider material to our business.
Competition
The medical/surgical supply distribution industry in the United States is highly competitive and characterized by intense pricing pressure. We compete with other national distributors and a number of regional and local distributors, as well as customer self-distribution models and, to a lesser extent, certain third-party logistics companies. Competitive factors within the medical/surgical supply distribution industry include market pricing, total delivered product cost, product availability, the ability to fill and invoice orders accurately, delivery time, range of services provided, efficient product sourcing, inventory management, information technology, electronic commerce capabilities, and the ability to meet customer-specific requirements. Our success is dependent on the ability to compete on the above factors, while managing internal costs and expenses. These competitive pressures could have a material adverse effect on our results of operations.
In addition, in recent years, the healthcare industry in the United States has experienced and continues to experience significant consolidation in response to cost containment legislation and general market pressures to reduce costs. This consolidation of our customers and suppliers generally gives them greater bargaining power to reduce the pricing available to them, which may adversely impact our results of operations.

7


The healthcare third-party logistics business in both the United States and abroad also is characterized by intense competition from a number of international, regional and local companies, including large conventional logistics companies that are moving into the healthcare and pharmaceutical distribution business. This competitive market places continuous pricing pressure on us from customers and manufacturers that could adversely affect our results of operations and financial condition if we are unable to continue to increase our revenues and to offset margin reductions caused by pricing pressures through cost control measures.
Dependence on Significant Healthcare Provider Customers
In 2014, our top ten customers in the United States represented approximately 26% of our consolidated net revenue. In addition, in 2014, approximately 82% of our consolidated net revenue was from sales to member hospitals under contract with our largest group purchasing organizations (GPO): Novation, MedAssets and Premier. We could lose a significant customer or GPO relationship if an existing contract expires without being replaced or is terminated by the customer or GPO prior to its expiration. Although the termination of our relationship with a given GPO would not necessarily result in the loss of all of the member hospitals as customers, any such termination of a GPO relationship, or a significant individual customer relationship, could have a material adverse effect on our results of operations.
Dependence on Significant Domestic Suppliers
In the United States, we distribute products from nearly 1,300 suppliers and are dependent on these suppliers for the continuing supply of products. In 2014, sales of products of our ten largest domestic suppliers accounted for approximately 57% of consolidated net revenue. We rely on suppliers to provide agreeable purchasing and delivery terms and performance incentives. Our ability to sustain adequate operating earnings has been, and will continue to be, partially dependent upon our ability to obtain favorable terms and incentives from suppliers, as well as suppliers continuing use of third-party distributors to sell and deliver their products. A change in terms by a significant supplier, or the decision of such a supplier to distribute its products directly to healthcare providers rather than through third-party distributors, could have a material adverse effect on our results of operations.
Integration of Acquisitions
In connection with our growth strategy, we from time to time acquire other businesses that we believe will expand or complement our existing businesses and operations. The integration of acquisitions involves a number of significant risks, which may include but are not limited to, the following:
Expenses and difficulties in the transition and integration of operations and systems;
Retention of current customers and the ability to obtain new customers;
The assimilation and retention of personnel, including management personnel, in the acquired businesses;
Accounting, tax, regulatory and compliance issues that could arise;
Difficulties in implementing uniform controls, procedures and policies in our acquired companies, or in remediating control deficiencies in acquired companies not formerly subject to the Sarbanes-Oxley Act of 2002;
Unanticipated expenses incurred or charges to earnings based on unknown circumstances or liabilities;
Failure to realize the synergies and other benefits we expect from the acquisition at the pace we anticipate;
General economic conditions in the markets in which the acquired businesses operate; and
Difficulties encountered in conducting business in markets where we have limited experience and expertise.
If we are unable to successfully complete and integrate our strategic acquisitions in a timely manner, our business, growth strategies and results of operations could be adversely affected.
International Operations
Operations outside the United States involve issues and risks, including but not limited to the following, any of which could have an adverse effect on our business and results of operations:
Lack of familiarity with and expertise in conducting business in foreign markets;
Foreign currency fluctuations and exchange risk;
Unexpected changes in foreign regulations or conditions relating to labor, economic or political environment, and social norms or requirements;
Adverse tax consequences and difficulties in repatriating cash generated or held abroad;
Local economic environments, such as in the European markets served by Movianto and ArcRoyal, including recession, inflation, indebtedness, currency volatility and competition; and

8


Changes in trade protection laws and other laws affecting trade and investment, including import/export regulations in both the United States and foreign countries.

International operations are also subject to risks of violation of laws that prohibit improper payments to and bribery of government officials and other individuals and organizations. These laws include the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act and other similar laws and regulations in foreign jurisdictions, any violation of which could result in substantial liability and a loss of reputation in the marketplace. Failure to comply with these laws also could subject us to civil and criminal penalties that could adversely affect our business and results of operations.
Changes in the Healthcare Environment in the United States
We, along with our customers and suppliers, are subject to extensive federal and state regulations relating to healthcare as well as the policies and practices of the private healthcare insurance industry. In recent years, there have been a number of government and private initiatives to reduce healthcare costs and government spending. These changes have included an increased reliance on managed care; reductions in Medicare and Medicaid reimbursement levels; consolidation of competitors, suppliers and customers; a shift in healthcare provider venues from acute care settings to clinics, physician offices and home care; and the development of larger, more sophisticated purchasing groups. All of these changes place additional financial pressure on healthcare provider customers, who in turn seek to reduce the costs and pricing of products and services provided by us. We expect the healthcare industry to continue to change significantly and these potential changes, which may include a reduction in government support of healthcare services, adverse changes in legislation or regulations, and further reductions in healthcare reimbursement practices, could have a material adverse effect on our results of operations.
The Affordable Care Act, enacted in 2010 includes, among other things, provisions for expanded Medicaid eligibility and access to healthcare insurance as well as increased taxes and fees on certain corporations and medical products. The provisions of the Affordable Care Act will not be fully implemented until 2018 and, although there is no way to predict the full impact of the law on the healthcare industry and our operations, its implementation may have an adverse effect on both customer purchasing and payment behavior and supplier product prices and terms of sale, all of which could adversely affect our results of operations.
Regulatory Requirements
We must comply with numerous laws and regulations in the United States, Europe, Asia and other countries where we operate. We also are required to hold permits and licenses and to comply with the operational and security standards of various governmental bodies and agencies. Any failure to comply with these laws and regulations or any failure to maintain the necessary permits, licenses or approvals, or to comply with the required standards, could disrupt our operations and/or adversely affect our results of operations and financial condition. In addition, we are subject to various federal and state laws intended to prevent healthcare fraud and abuse. The requirements of these fraud and abuse laws are complicated and subject to interpretation and may be applied by a regulator, prosecutor or judge in a manner that could negatively impact us financially or operationally.
Recalls and Product Liability Claims
Certain of the products that we sell and distribute are sourced and sold under one or more private labels or are assembled by us into custom trays and minor procedure kits. If these products do not function as designed, are inappropriately designed or are not properly produced, we may have to withdraw such products from the market and/or be subject to product liability claims. Although we maintain insurance against product liability and defense costs in amounts believed to be reasonable, there is no assurance that we can successfully defend any such claims or that the insurance we carry will be sufficient. A successful claim against us in excess of insurance coverage could have a material adverse impact on our business and results of operations.
General Economic Climate
Poor or deteriorating economic conditions in the United States and the other countries in which we conduct business could adversely affect the demand for healthcare services and consequently, the demand for our products and services. Poor economic conditions also could lead our suppliers to offer less favorable terms of purchase to distributors, which would negatively affect our profitability. These and other possible consequences of financial and economic decline could materially and adversely affect our business and results of operations.

9


Bankruptcy, Insolvency or other Credit Failure of Customers
We provide credit in the normal course of business to customers. We perform initial and ongoing credit evaluations of customers and maintain reserves for credit losses. The bankruptcy, insolvency or other credit failure of one or more customers with substantial balances due to us could have a material adverse effect on our results of operations.
Reliance on Information Systems and Technological Advancement
We rely on information systems to receive, process, analyze and manage data in distributing thousands of inventory items to customers from numerous distribution and logistics centers. These systems are also relied upon for billings to and collections from customers, as well as the purchase of and payment for inventory and related transactions from our suppliers. In addition, the success of our long-term growth strategy is dependent upon the ability to continually monitor and upgrade our information systems to provide better service to customers. Our business and results of operations may be materially adversely affected if systems are interrupted or damaged by unforeseen events (including cyber attacks) or fail to operate for an extended period of time, or if we fail to appropriately enhance our systems to support growth and strategic initiatives.
Changes in Tax Laws
We operate throughout the United States and Europe as well as in China. As a result, we are subjected to the tax laws and regulations of the United States federal, state and local governments and of various foreign jurisdictions. From time to time, legislative and regulatory initiatives are proposed, including but not limited to proposals to repeal LIFO (last-in, first-out) treatment of domestic inventory or changes in tax accounting methods for inventory or other tax items, that could adversely affect our tax positions, tax rate or cash payments for taxes.
Item 1B. Unresolved Staff Comments
None.
Item 2. Properties
Our Domestic segment had 42 distribution centers as well as office and warehouse space across the United States as of December 31, 2014. We lease all of the centers from unaffiliated third parties with the exception of one location which we own. We also lease offices in China and Malaysia as well as small offices for sales and consulting personnel across the United States. In addition, we have a warehousing arrangement in Honolulu, Hawaii, with an unaffiliated third party, and lease space on a temporary basis from time to time to meet our inventory storage needs. We also operate two packaging facilities in our Domestic segment, one of which is owned and the other is subject to a capital lease. We own an office building in Brentwood, New York which is held for sale as of December 31, 2014. We also own our corporate headquarters building, and adjacent acreage, in Mechanicsville, Virginia, a suburb of Richmond, Virginia.
Our International segment properties span 12 European countries and include 26 logistics centers (22 leased and four owned) and one packaging facility that is owned. We also operate seven transport depots, of which we lease six and own one. We also lease office space in Bedford, UK.
We regularly assess our business needs and make changes to the capacity and location of distribution and logistics centers. We believe that our facilities are adequate to carry on our business as currently conducted. A number of leases are scheduled to terminate within the next several years. We believe that, if necessary, we could find facilities to replace these leased premises without suffering a material adverse effect on our business.
Item 3. Legal Proceedings
We are subject to various legal actions that are ordinary and incidental to our business, including contract disputes, employment, workers’ compensation, product liability, regulatory and other matters. We establish reserves from time to time based upon periodic assessment of the potential outcomes of pending matters. In addition, we believe that any potential liability arising from employment, product liability, workers’ compensation and other personal injury litigation matters would be adequately covered by our insurance coverage, subject to policy limits, applicable deductibles and insurer solvency. While the outcome of legal actions cannot be predicted with certainty, we believe, based on current knowledge and the advice of counsel, that the outcome of these currently pending matters, individually or in the aggregate, will not have a material adverse effect on our financial condition or results of operations.



Part II

10



Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities
Owens & Minor, Inc.’s common stock trades on the New York Stock Exchange under the symbol OMI. As of January 27, 2015, there were approximately 3,382 common shareholders of record. We believe there are an estimated additional 26,920 beneficial holders of our common stock. See Selected Quarterly Financial Information in Item 15 of this report for high and low closing sales prices of our common stock and quarterly cash dividends per common share and Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, for a discussion of our dividend payments.
5-Year Total Shareholder Return
In the past, we have presented line graphs comparing the cumulative total return of our common shares with the cumulative total return of the Standard & Poor's Composite- 500 Index (S&P 500 Index) and an Industry Peer Group (which includes the companies listed below). This year we have also included a comparison against the Standard & Poor's Composite-500 Healthcare Index (S&P 500 Healthcare Index), an independently prepared index that includes more than 50 companies in the healthcare industry. Next year, we do not intend to include the Industry Peer Group in our comparison. We are changing to the S&P 500 Healthcare Index because we believe it provides a better alignment with industry changes and less focus on specific business models or practices. We also believe it to be a commonly used index by large healthcare industry companies. This graph assumes that the value of the investment in the common stock and each index was $100 on December 31, 2009, and that all dividends were reinvested.
The Industry Peer Group, weighted by market capitalization, consists of pharmaceutical and/or medical product distribution companies: AmerisourceBergen Corporation, Cardinal Health, Inc., McKesson Corporation, Henry Schein, Inc., and Patterson Companies, Inc.

 
Base
Period
 
Years Ended
Company Name / Index
12/2009
 
12/2010
 
12/2011
 
12/2012
 
12/2013
 
12/2014
Owens & Minor, Inc.
$
100.00

 
$
105.42

 
$
102.24

 
$
108.13

 
$
142.63

 
$
140.99

S&P 500 Index
100.00

 
115.06

 
117.49

 
136.30

 
180.44

 
205.14

S&P 500 Healthcare
100.00

 
102.90

 
116.00

 
136.75

 
193.45

 
242.47

Peer Group
100.00

 
119.02

 
129.37

 
152.33

 
244.92

 
309.12


11


Share Repurchase Program. In February 2014, our Board of Directors authorized a share repurchase program of up to $100 million of our outstanding common stock to be executed at the discretion of management over a three-year period, expiring in February 2017. The program is intended to offset shares issued in conjunction with our stock incentive plan and return capital to shareholders. The program may be suspended or discontinued at any time. During the year ended December 31, 2014, we repurchased in open-market transactions and retired approximately 0.3 million shares at an average price per share of $34.31.
We did not repurchase any shares during the fourth quarter of 2014.


12


Item 6. Selected Consolidated Financial Data
(in thousands, except ratios and per share data)
 
At or for the Year Ended December 31,
 
2014 (1)
 
2013 (2)
 
2012 (3)
 
2011 (4)
 
2010 (5)
Summary of Operations:

 

 

 

 

Net revenue
$
9,440,182

 
$
9,071,532

 
$
8,868,324

 
$
8,627,912

 
$
8,123,608

Net income
$
66,503

 
$
110,882

 
$
109,003

 
$
115,198

 
$
110,579

 
 
 
 
 
 
 
 
 
 
Per Common Share(6) :
 
 

 

 

 

Net income per share—basic
$
1.06

 
$
1.76

 
$
1.72

 
$
1.82

 
$
1.76

Net income per share—diluted
$
1.06

 
$
1.76

 
$
1.72

 
$
1.81

 
$
1.75

Cash dividends
$
1.000

 
$
0.960

 
$
0.880

 
$
0.800

 
$
0.708

Stock price at year end
$
35.11

 
$
36.56

 
$
28.51

 
$
27.79

 
$
29.43

 
 
 
 
 
 
 
 
 
 
Summary of Financial Position:
 
 

 

 

 

Total assets
$
2,735,406

 
$
2,324,042

 
$
2,214,398

 
$
1,946,815

 
$
1,822,039

Cash and cash equivalents
$
56,772

 
$
101,905

 
$
97,888

 
$
135,938

 
$
159,213

Total debt
$
613,809

 
$
216,243

 
$
217,591

 
$
214,556

 
$
210,906

Total Owens & Minor, Inc. shareholders’ equity
$
990,838

 
$
1,023,913

 
$
972,526

 
$
918,087

 
$
857,518

 
 
 
 
 
 
 
 
 
 
Selected Ratios:
 
 

 

 

 

Gross margin as a percent of revenue
12.39
%
 
12.31
%
 
10.43
%
 
9.94
%
 
9.94
%
Selling, general, and administrative expenses as a percent of revenue
9.82
%
 
9.52
%
 
7.70
%
 
7.08
%
 
6.94
%
Operating earnings as a percent of revenue
1.69
%
 
2.18
%
 
2.22
%
 
2.36
%
 
2.41
%
Days sales outstanding (DSO) (7)
22.1

 
22.1

 
20.8

 
20.7

 
19.6

Average annual inventory turnover (8)
10.1

 
10.4

 
10.1

 
10.2

 
10.4

 ____________________________
(1)
We incurred charges of $42.8 million ($35.3 million after tax, or $0.56 per common share) associated with acquisition-related and exit and realignment activities in 2014, a loss on estimated claim settlement of $3.9 million ($3.9 million after tax, or $0.06 per common share), a net gain of $3.7 million ($4.7 million after tax, or $0.07 per common share) associated with fair value adjustments related to purchase accounting, and a loss on early retirement of debt of $14.9 million ($9.1 million after tax or $0.14 per common share). See Notes 3 and 9 of Notes to Consolidated Financial Statements.
(2)
We incurred charges of $12.4 million ($8.9 million after tax, or $0.14 per common share) associated with acquisition-related and exit and realignment activities in 2013. See Notes 3 and 9 of Notes to Consolidated Financial Statements.
(3)
We incurred charges of $10.2 million ($8.2 million after tax, or $0.13 per common share) associated with acquisition-related and exit and realignment activities in 2012. See Notes 3 and 9 of Notes to Consolidated Financial Statements.
(4)
We incurred charges of $13.2 million ($8.0 million after tax, or $0.13 per common share) associated with acquisition-related and exit and realignment activities in 2011. See Note 9 of Notes to Consolidated Financial Statements.
(5)
We terminated our frozen defined benefit pension plan in the fourth quarter of 2010 and recognized a settlement charge of $19.6 million ($11.9 million after tax, or $0.19 per common share).
(6)
On March 31, 2010, we effected a three-for-two stock split of our outstanding shares of common stock in the form of a stock dividend of one share of common stock for every two shares outstanding to stockholders of record on March 15, 2010. The common stock began trading on a post-split basis on April 1, 2010. All share and per-share data (except par value) have been adjusted to reflect this split.

13


(7)
Based on net revenue for the fourth quarter of the year.
(8)
Based on cost of goods sold for the preceding 12 months.


14


Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Management’s discussion and analysis of financial condition and results of operations is intended to assist the reader in the understanding and assessment of significant changes and trends related to the results of operations of the Company together with its subsidiaries. The discussion and analysis presented below refers to, and should be read in conjunction with, the consolidated financial statements and accompanying notes included in Item 8 of Part II of this Annual Report on Form 10-K.
Overview
Owens & Minor, Inc., along with its subsidiaries, (we, us, or our) is a leading national distributor of name-brand medical and surgical supplies and a healthcare logistics company. We report our business under two segments: Domestic and International. Our Domestic segment includes all operations in the United States relating to our role as a healthcare logistics company providing distribution, packaging and logistics services to healthcare providers and manufacturers. The International segment consists of our European third-party logistics and packaging businesses. Segment financial information is provided in Note 20 of Notes to Consolidated Financial Statements included in this annual report.
Financial Highlights.
The following table provides a reconciliation of reported operating earnings, net income and diluted net income per common share to non-GAAP measures used by management:

For the years ended December 31,
(Dollars in thousands, except per share data)
2014
 
2013
 
2012
Operating earnings, as reported (GAAP)
$
159,536

 
$
198,083

 
$
196,753

Acquisition-related and exit and realignment charges (1)
42,801

 
12,444

 
10,164

Fair value adjustments related to purchase accounting (2)
(3,706
)
 

 

Other (3)
3,907

 

 

Operating earnings, adjusted (non-GAAP) (Adjusted Operated Earnings)
$
202,538

 
$
210,527

 
$
206,917

Adjusted Operating Earnings as a percent of revenue (non-GAAP)
2.15
%
 
2.32
%
 
2.33
%
 
 
 
 
 
 
Net income as reported (GAAP)
$
66,503

 
$
110,882

 
$
109,003

Acquisition-related and exit and realignment charges, net of tax (1)
35,302

 
8,856

 
8,200

Fair value adjustments related to purchase accounting, net of tax (2)
(4,703
)
 

 

Other, net of tax (3)
3,907

 

 

Loss on early retirement of debt, net of tax (4)
9,092

 

 

Net income, adjusted (non-GAAP) (Adjusted Net Income)
$
110,101

 
$
119,738

 
$
117,203

 
 
 
 
 
 
Net income per diluted common share, as reported (GAAP)
$
1.06

 
$
1.76

 
$
1.72

Acquisition-related and exit and realignment charges, net of tax (1)
0.56

 
0.14

 
0.13

Fair value adjustments related to purchase accounting, net of tax (2)
(0.07
)
 

 

Other, net of tax (3)
0.06

 

 

Loss on early retirement of debt, net of tax (4)
0.14

 

 

Net income per diluted common share, adjusted (non-GAAP) (Adjusted EPS)
$
1.76

 
$
1.90

 
$
1.85


The following items have been excluded in our non-GAAP financial measures:
(1) Acquisition-related charges, pre-tax, were $16.1 million in 2014, $3.5 million in 2013 and $10.5 million in 2012. Current year charges consist primarily of costs incurred to perform due diligence and analysis related to the Medical Action and Arc Royal acquisitions, costs to complete the transactions, and costs to begin the integration of the acquired operations (including certain severance and contractual payments to former management) as well as certain costs in Movianto to resolve issues and claims with the former owner. Charges in 2013 included costs to transition the information technology and other operations and administrative functions of Movianto from the former owner. Acquisition-related charges in 2012 were primarily transaction costs incurred with Movianto to perform due diligence and to analyze, negotiate and consummate the acquisition as well as costs to perform certain post-closing activities to establish the organizational structure.

15


Exit and realignment charges (income), pre-tax, were $26.7 million in 2014, $8.9 million in 2013 and $(0.4) million in 2012. These charges were associated with optimizing our operations and include the closure and consolidation of certain distribution and logistics centers, administrative offices and warehouses in the United States and Europe. These charges also include other costs associated with our strategic organizational realignment which include management changes, certain professional fees, and costs to streamline administrative functions and processes. Further information regarding these items is included in Note 9 of Notes to Consolidated Financial Statements.
(2) The fourth quarter of 2014 includes a gain of $6.7 million (pretax) recorded in other operating income, net from a fair value adjustment to contingent consideration related to the 2012 Movianto acquisition purchase price, offset by the incremental charge to cost of goods sold of $3.0 million (pretax) from purchase accounting impacts related to the sale of acquired inventory that was written up to fair value in connection with the current year acquisitions.
(3) The fourth quarter of 2014 includes a loss in other operating income, net related to an accrual for the estimated settlement amount of a breach of contract claim in the United Kingdom for $3.9 million (pretax).
(4) In 2014, we repaid our 2016 Notes and recorded a net loss on the early retirement of $14.9 million (pretax), which includes the redemption premium offset by the recognition of a gain on previously settled interest rate swaps.
These charges have been tax effected in the preceding table by determining the income tax rate depending on the amount of charges incurred in different tax jurisdictions and the deductibility of those charges for income tax purposes. More information about these charges is provided in Notes 3, 9 and 10 of Notes to Consolidated Financial Statements included in this annual report.
Adjusted EPS decreased to $1.76 in 2014 from $1.90 in 2013 primarily due to a decrease in Adjusted Operating Earnings of $8.0 million and an increase in interest expense of $5.1 million.
Domestic segment operating earnings were $209.3 million for 2014, a decrease of $2.7 million when compared to the prior year. International segment operating losses were $6.7 million for 2014 compared to $1.4 million in 2013. The higher operating loss in the International segment was largely attributable to the loss of certain customers in the United Kingdom early in 2014 as well as increased costs in the United Kingdom to transition a significant new customer. The Domestic segment experienced lower margins on new and renewed customer contracts in 2014 compared to 2013 and higher SG&A costs to support sales growth. The Domestic segment operating earnings included a $5.3 million recovery in the first quarter from the settlement of a direct purchaser, anti-trust class-action lawsuit related to the purchases of medical devices which, for the year, was largely offset by increased legal fees related to ongoing litigation.
Use of Non-GAAP Measures
Adjusted operating earnings, adjusted net income and adjusted EPS are an alternative view of performance used by management, and we believe that investors' understanding of our performance is enhanced by disclosing these performance measures. In general, the measures exclude items and charges that (i) management does not believe reflect our core business and relate more to strategic, multi-year corporate activities; or (ii) relate to activities or actions that may have occurred over multiple or in prior periods without predictable trends. Management uses these non-GAAP financial measures internally to evaluate our performance, evaluate the balance sheet, engage in financial and operational planning and determine incentive compensation.

Management provides these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on our financial and operating results and in comparing our performance to that of our competitors. However, the non-GAAP financial measures used by us may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.

The non-GAAP financial measures disclosed by us should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth above should be carefully evaluated.


16


Results of Operations
2014 compared to 2013
Net revenue.
For the years ended December 31,
 
Change
(Dollars in thousands)
2014
 
2013
 
$
 
%
Domestic
$
8,951,852

 
$
8,688,018

 
$
263,834

 
3.0
%
International
488,330

 
383,514

 
104,816

 
27.3
%
Net revenue
$
9,440,182

 
$
9,071,532

 
$
368,650

 
4.1
%
Consolidated net revenue improved in our two segments for the year ended December 31, 2014. Excluding the impact of the fourth quarter acquisitions, net revenue increased by 2.6% and 25.5% in our Domestic and International segments, respectively. In the Domestic segment, the continued trend of growth in our existing large healthcare provider customer accounts and new business exceeded declines from smaller customers when compared to prior year. Domestic segment growth rates are impacted by ongoing market trends including healthcare utilization rates. The increases in the International segment were a result of new buy/sell contracts and growth in fee-for-service business as well as positive impacts from foreign exchange. Fee-for-service business generally represents approximately two-thirds of net revenue in the International segment.
Cost of goods sold.
For the years ended December 31,
 
Change
(Dollars in thousands)
2014
 
2013
 
$
 
%
Cost of goods sold
$
8,270,216

 
$
7,954,457

 
$
315,759

 
4.0
%
Cost of goods sold includes the cost of the product (net of supplier incentives and cash discounts) and all costs incurred for shipments of products from manufacturers to our distribution centers for all customer arrangements where we are the primary obligor, bear the risk of general and physical inventory loss and carry all credit risk associated with sales. These are sometimes referred to as distribution or buy/sell contracts. Beginning in the fourth quarter of 2014, cost of goods sold also includes direct and certain indirect labor, material and overhead costs associated with our acquired packaging operations. There is no cost of goods sold associated with our fee-for-service business. As a result of the increase in distribution sales activity and fourth quarter sales activity associated with the acquisitions (which includes the incremental charge to cost of goods sold of $3.0 million from purchase accounting impacts related to the sale of acquired inventory that was written up to fair value), cost of goods sold increased $315.8 million from 2013. See the gross margin discussion below for additional factors impacting cost of goods sold.
Gross margin.
For the years ended December 31,
 
Change
(Dollars in thousands)
2014
 
2013
 
$
 
%
Gross margin
$
1,169,966

 
$
1,117,075

 
$
52,891

 
4.7
%
As a % of net revenue
12.39
%
 
12.31
%
 
 
 
 
The growth in fee-for-service activity drove the overall improvement in gross margin as the International segment showed a $44.2 million increase over the prior year. Domestic segment gross margin for the year benefitted from increased sales volume and the fourth quarter contribution of Medical Action which offset the decline in margins on new and renewed customer contracts in 2014 when compared to 2013.
We value Domestic segment inventory under the LIFO method. Had inventory been valued under the first-in, first-out (FIFO) method, gross margin as a percentage of net revenue would have been higher by 8 basis points in 2014 and lower by 3 basis points in 2013.

17


Operating expenses.
For the years ended December 31,
 
Change
(Dollars in thousands)
2014
 
2013
 
$
 
%
SG&A expenses
$
926,977

 
$
863,656

 
$
63,321

 
7.3
%
As a % of net revenue
9.82
%
 
9.52
%
 
 
 
 
Depreciation and amortization
$
57,125

 
$
50,586

 
$
6,539

 
12.9
%
Other operating income, net
$
(16,473
)
 
$
(7,694
)
 
$
(8,779
)
 
114.1
%
Selling, general and administrative (SG&A) expenses include labor and warehousing costs associated with our distribution and logistics services and all costs associated with our fee-for-service arrangements. Shipping and handling costs are included in SG&A expenses and include costs to store, move, and prepare products for shipment, as well as costs to deliver products to customers. The costs to convert new customers to our service platform are generally incurred prior to the recognition of revenues from the new customers.
International segment SG&A expenses increased over the prior year by $44.4 million due mainly to increased salaries and delivery costs associated with higher fee-for-service activity as well as increased costs associated with integrating a significant new customer in the United Kingdom earlier in the year. The Domestic segment also experienced an increase during the year as a result of higher accrued incentive compensation, warehouse expense from greater sales activity and higher legal fees compared to prior year. Current year acquisitions accounted for $11.3 million of the increase in SG&A from prior year.
Depreciation and amortization expense increased primarily in the International segment due to increases in computer software amortization for assets placed in service and amortization from intangibles associated with purchase price accounting. An additional $1.6 million in expense is associated with the current year acquisitions. In connection with Medical Action and ArcRoyal, approximately $0.3 million in depreciation expense is also included in cost of goods sold.
The increase in other operating income, net for the year ended December 31, 2014 is attributed primarily to (1) the recovery of $5.3 million from the settlement of a direct purchaser anti-trust class action lawsuit relating to the recovery of costs from purchases of medical devices over a multi-year period, as well as a gain on the sale of an investment, (2) a gain of $6.7 million from a fair value adjustment to contingent consideration related to the Movianto acquisition purchase price, offset by (3) a loss of $3.9 million related to an accrual for the estimated settlement amount of a breach of contract claim in the United Kingdom.
A discussion of the acquisition-related and exit and realignment charges is included above in the Overview section.
Interest expense, net.
For the years ended December 31,
 
Change
(Dollars in thousands)
2014
 
2013
 
$
 
%
Interest expense, net
$
18,163

 
$
13,098

 
$
5,065

 
38.7
%
Effective interest rate
5.38
%
 
6.05
%
 
 
 
 
The increase in interest expense from the prior year is attributed to the new Senior Notes issued on September 16, 2014 which are more fully described in the Capital resources section and in Note 10 of Notes to Consolidated Financial Statements.
Income taxes.
For the years ended December 31,
 
Change
(Dollars in thousands)
2014
 
2013
 
$
 
%
Income tax provision
$
59,980

 
$
74,103

 
$
(14,123
)
 
(19.1
)%
Effective tax rate
47.4
%
 
40.1
%
 
 
 
 
The increase in the effective tax rate, including income taxes on acquisition-related and exit and realignment charges as well as the loss on early retirement of debt, increased from the prior year periods largely due to the impact of foreign taxes and the effect of certain acquisition-related costs which are not deductible for tax purposes.

18


2013 compared to 2012
Net revenue.
For the years ended December 31,
 
Change
(Dollars in thousands)
2013
 
2012
 
$
 
%
Domestic
$
8,688,018

 
$
8,731,484

 
$
(43,466
)
 
(0.5
)%
International
383,514

 
136,840

 
246,674

 
180.3
 %
Net revenue
$
9,071,532

 
$
8,868,324

 
$
203,208

 
2.3
 %
Net revenue for 2013 increased due to a full year of activity in our International segment compared to four months in 2012. Domestic segment revenue continued to be impacted by ongoing market trends including lower rates of healthcare utilization. In addition, our continued rationalization of smaller, less profitable healthcare provider customers and suppliers and reduced government purchases were not fully offset by growth in existing customers, fee-for-service and new business. Fee-for-service business represented approximately two-thirds of net revenue in the International segment.
Cost of goods sold.
For the years ended December 31,
 
Change
(Dollars in thousands)
2013
 
2012
 
$
 
%
Cost of goods sold
$
7,954,457

 
$
7,943,670

 
$
10,787

 
0.1
%
Cost of goods sold includes the cost of the product (net of supplier incentives and cash discounts) and all costs incurred for shipments of products from manufacturers to our distribution centers for all customer arrangements where we are the primary obligor, bear the risk of general and physical inventory loss and carry all credit risk associated with sales. These are sometimes referred to as distribution or buy/sell contracts. There is no cost of goods sold associated with our fee-for-service business. As a result of the increases in distribution sales activity, cost of goods sold increased $10.8 million from 2012. See the gross margin discussion below for additional factors impacting cost of goods sold.
Gross margin.
For the years ended December 31,
 
Change
(Dollars in thousands)
2013
 
2012
 
$
 
%
Gross margin
$
1,117,075

 
$
924,654

 
$
192,421

 
20.8
%
As a % of net revenue
12.31
%
 
10.43
%
 
 
 
 
Gross margin increased primarily due to a full year of Movianto activity in 2013 which contributed $177.4 million to the year over year change. The Domestic segment gross margin benefitted from strategic initiatives including growth in fee-for-service business during 2013 and supplier price changes in the first and second quarters of 2013 at a higher level than in 2012.
We value Domestic segment inventory under the LIFO method. Had inventory been valued under the first-in, first-out (FIFO) method, gross margin as a percentage of net revenue would have been lower by 3 basis points in 2013 and higher by 5 basis points in 2012.
Operating expenses.
For the years ended December 31,
 
Change
(Dollars in thousands)
2013
 
2012
 
$
 
%
SG&A expenses
$
863,656

 
$
682,595

 
$
181,061

 
26.5
%
As a % of net revenue
9.52
%
 
7.70
%
 
 
 
 
Depreciation and amortization
$
50,586

 
$
39,604

 
$
10,982

 
27.7
%
Other operating income, net
$
(7,694
)
 
$
(4,462
)
 
$
(3,232
)
 
72.4
%

19


Selling, general and administrative (SG&A) expenses include labor and warehousing costs associated with our distribution and logistics services and all costs associated with our fee-for-service arrangements. Distribution costs are included in SG&A expenses and include costs to store, move, and prepare products for shipment, as well as costs to deliver products to customers. The costs to convert new customers to our information systems are generally incurred prior to the recognition of revenues from new customers. The International segment also included costs for information technology and other transition services provided by the former owners of Movianto which were substantially completed in 2013.
SG&A expense increased by $165.4 million in 2013 compared to 2012 due to a full year of activity in Movianto. Domestic SG&A expense also increased over 2012 due to greater fee-for-service sales activity, increased costs to support strategic initiatives and higher costs associated with workers' compensation, litigation and healthcare. During the second quarter of 2013, we reached a settlement in the administrative proceedings before the California Board of Equalization related to certain municipal sales tax incentives. As a result, SG&A expenses were reduced in 2013 by a net amount of $4.3 million, which was fully offset by the increased costs noted above. In the future, the company expects to receive an ongoing tax incentive that will vary with eligible revenues generated by sales to California-based customers. More information about this incentive is provided in Note 18 of Notes to Consolidated Financial Statements included in this annual report.
Depreciation and amortization expense increased in 2013 primarily related to warehouse equipment and information technology hardware and software acquired with Movianto. In addition, depreciation and amortization increased $0.8 million in the Domestic segment due to software enhancements for operational efficiency improvements.
Other operating income included finance charge income of $6.0 million and $4.9 million in 2013 and 2012. The increase over 2012 was due to a $1.6 million increase in income associated with product financing arrangements with customers in Europe, $0.8 million in foreign exchange gains and a net $0.9 million in Domestic charges incurred in 2012 associated with specific litigation matters and loss contingency expenses which did not recur in 2013.
A discussion of the acquisition-related and exit and realignment charges is included above in the Overview section.
Interest expense, net.
For the years ended December 31,
 
Change
(Dollars in thousands)
2013
 
2012
 
$
 
%
Interest expense, net
$
13,098

 
$
13,397

 
$
(299
)
 
(2.2
)%
Effective interest rate
6.05
%
 
6.17
%
 
 
 
 
 For 2013, the decrease in interest expense was primarily from lower commitment fees in our new revolving credit facility effective June 2012, partially offset by less interest income earned on cash and cash equivalents.
Income taxes.
For the years ended December 31,
 
Change
(Dollars in thousands)
2013
 
2012
 
$
 
%
Income tax provision
$
74,103

 
$
74,353

 
$
(250
)
 
(0.3
)%
Effective tax rate
40.1
%
 
40.6
%
 
 
 
 
The provision for income taxes decreased from 2012 due to the impact of non-deductible acquisition-related costs in 2012 incurred as a result of the Movianto acquisition as well as results of benefits recognized in 2013 upon the conclusion of examinations of our 2009 and 2010 Federal and certain state income tax returns. These benefits were partially offset by the impact of foreign taxes.

20


Financial Condition, Liquidity and Capital Resources
Financial condition. We monitor operating working capital through days sales outstanding (DSO) and merchandise inventory turnover. We estimate a hypothetical increase (decrease) in DSO of one day would result in a decrease (increase) in our cash balances, an increase (decrease) in borrowings against our revolving credit facility, or a combination thereof of approximately $28 million.
The majority of our cash and cash equivalents are held in cash depository accounts with major banks in the United States and Europe or invested in high-quality, short-term liquid investments. Changes in our working capital can vary in the normal course of business based upon the timing of inventory purchases, collection of accounts receivable, and payment to suppliers.
 
For the years ended December 31,
 
Change
(Dollars in millions)
2014
 
2013
 
$
 
%
Cash and cash equivalents
$
56.8

 
$
101.9

 
$
(45.1
)
 
(44.3
)%
Accounts and notes receivable, net of allowances
$
626.2

 
$
572.9

 
$
53.3

 
9.3
 %
Consolidated DSO (1)
22.1

 
22.1

 

 

Merchandise inventories
$
872.5

 
$
771.7

 
$
100.8

 
13.1
 %
Consolidated inventory turnover (2)
10.1

 
10.4

 

 

Accounts payable
$
608.8

 
$
643.9

 
$
(35.1
)
 
(5.5
)%
(1) Based on year end accounts receivable and net revenue for the fourth quarter
(2) Based on average annual inventory and costs of goods sold for the years ended December 31, 2014 and 2013

Liquidity and capital expenditures. The following table summarizes our consolidated statements of cash flows for the years ended December 31, 2014, 2013 and 2012: 
(Dollars in millions)
2014
 
2013
 
2012
Net cash provided by (used for) continuing operations:
 
 
 
 
 
Operating activities
$
(3.8
)
 
$
140.6

 
$
218.5

Investing activities
(317.3
)
 
(57.1
)
 
(190.8
)
Financing activities
278.6

 
(82.0
)
 
(68.4
)
Effect of exchange rate changes on cash
(2.7
)
 
2.5

 
2.7

Increase (decrease) in cash and cash equivalents
$
45.1

 
$
4.0

 
$
(38.0
)
Cash used for operating activities in 2014 reflected unfavorable changes in working capital driven primarily by the timing of vendor payments and increased net working capital needs resulting from strong sales growth. Depreciation and amortization in the statement of cash flow for 2014 includes $6.0 million in accelerated amortization which is included in acquisition-related and exit and realignment charges in the statement of income related to the change in useful life (from 10 years to 1 year) for an information system which is being replaced in the International segment. Cash from operating activities for 2013 decreased compared to 2012 due to changes in working capital, including increases in accounts and notes receivable which experienced an increase in DSO of 1.3 days (unfavorable impact on cash of $33.3 million).
Cash used for investing activities in 2014 included cash paid for the acquisitions of Medical Action and Arc Royal of approximately $261.6 million plus assumed third-party debt (capital lease obligations) of $13.4 million and capital expenditures of $70.8 million (compared to $60.1 million in 2013) primarily related to distribution center and logistics facility moves and modifications and information technology initiatives. In 2012, we acquired Movianto in exchange for approximately $155.2 million of cash plus assumed third-party debt (primarily capitalized leases) of $2.1 million. Domestic segment capital expenditures were $34.5 million in 2012, primarily related to our strategic and operational efficiency initiatives, particularly initiatives relating to information technology enhancements.
In 2014, cash provided by financing activities reflects proceeds from borrowings of $581.4 million and the repayment of long-term debt of $217.4 million. We paid dividends of $63.1 million, $60.7 million and $55.7 million and repurchased common stock under a share repurchase program for $9.9 million, $18.9 million and $15.0 million in the years ended December 31, 2014, 2013 and 2012.

21


Capital resources. Our sources of liquidity include cash and cash equivalents and a revolving credit facility. On September 17, 2014, we amended our existing Credit Agreement with Wells Fargo Bank, N.A., JPMorgan Chase Bank, N.A., Bank of America, N.A. and a syndicate of financial institutions (the Amended Credit Agreement) increasing our borrowing capacity from $350 million to $450 million and extending the term through 2019. Under the Amended Credit Agreement, we have the ability to request two one -year extensions and to request an increase in aggregate commitments by up to $200 million. The interest rate on the Amended Credit Agreement, which is subject to adjustment quarterly, is based on the London Interbank Offered Rate (LIBOR), the Federal Funds Rate or the Prime Rate, plus an adjustment based on the better of our debt ratings or leverage ratio (Credit Spread) as defined by the Amended Credit Agreement. We are charged a commitment fee of between 12.5 and 25.0 basis points on the unused portion of the facility. The terms of the Amended Credit Agreement limit the amount of indebtedness that we may incur and require us to maintain ratios for leverage and interest coverage, including on a pro forma basis in the event of an acquisition. We may utilize the revolving credit facility for long-term strategic growth, capital expenditures, working capital and general corporate purposes. If we were unable to access the revolving credit facility, it could impact our ability to fund these needs. Based on our leverage ratio at December 31, 2014, the interest rate under the credit facility is LIBOR plus 1.375%.
At December 31, 2014 , we had $33.7 million in borrowings and letters of credit of approximately $5.0 million outstanding under the Amended Credit Agreement, leaving $411 million available for borrowing. We also have a $1.5 million letter of credit outstanding as of December 31, 2014 and 2013, which supports our facilities leased in Europe.

On September 16, 2014, we issued $275 million of 3.875% senior notes due 2021 (the “2021 Notes”) and $275 million of 4.375% senior notes due 2024 (the “2024 Notes”). The 2021 Notes were sold at 99.5% of the principal amount with an effective yield of 3.951%. The 2024 Notes were sold at 99.6% of the principal amount with an effective yield of 4.422%. Interest on the 2021 Notes and 2024 Notes is payable semiannually in arrears, commencing on March 15, 2015 and December 15, 2014, respectively. We have the option to redeem the 2021 Notes and 2024 Notes in part or in whole prior to maturity at a redemption price equal to the greater of 100% of the principal amount or the present value of the remaining scheduled payments discounted at the Treasury Rate plus 30 basis points. We are deferring and amortizing over the respective terms $5.3 million in costs incurred in connection with the issuance of the 2021 Notes and the 2024 Notes.

We used a portion of the proceeds from the 2021 Notes and the 2024 Notes to complete the Medical Action and ArcRoyal acquisitions in the fourth quarter for a combined purchase price of $261.6 million, net of cash acquired, and including debt assumed of $13.4 million (capitalized lease obligations). We also used a portion of the proceeds to fund the early retirement of all of our 2016 Notes, which included the payment of a $17.4 million redemption premium. We recorded a net loss on the early retirement of our 2016 Notes of $14.9 million, which includes the redemption premium offset by the recognition of a gain on previously settled interest rate swaps.
The IRS on January 10, 2014 released final regulations relating to the adjustment of inventory costs for certain sales based vendor charge-backs and the allowable treatment of these charge-backs in tax LIFO calculations. Based upon a 2013 accounting method change filed with the IRS and current regulatory guidance and case law we do not believe that these regulations will have a material impact on our financial statements or cash flow.
We paid quarterly cash dividends on our outstanding common stock at the rate of $0.25 per share during 2014, $0.24 per share during 2013, and $0.22 per share during 2012. Our annual dividend payout ratio for the three years ended December 31, 2014, based on Adjusted EPS, was in the range of 47.6% to 57.1%. In February 2015, the Board of Directors approved a 1.0% increase in the amount of our quarterly dividend to $0.2525 per common share. We anticipate continuing to pay quarterly cash dividends in the future. However, the payment of future dividends remains within the discretion of the Board of Directors and will depend upon our results of operations, financial condition, capital requirements and other factors.
In February 2014, the Board of Directors authorized a share repurchase program of up to $100 million of our outstanding common stock to be executed at the discretion of management over a three-year period, expiring in February 2017. The program is intended to offset shares issued in conjunction with our stock incentive plan and may be suspended or discontinued at any time. During 2014, we repurchased approximately 0.3 million shares at $9.9 million under this program. At December 31, 2014, the remaining amount authorized for repurchase under this program was $90.1 million.
We believe available financing sources, including cash generated by operating activities and borrowings under the Amended Credit Agreement, will be sufficient to fund our working capital needs, capital expenditures, long-term strategic growth, payments under long-term debt and lease arrangements, payments of quarterly cash dividends, share repurchases and other cash requirements. While we believe that we will have the ability to meet our financing needs in the foreseeable future, changes in economic conditions may impact (i) the ability of financial institutions to meet their contractual commitments to us, (ii) the ability of our customers and suppliers to meet their obligations to us or (iii) our cost of borrowing.


22


We earn a portion of our operating earnings in foreign jurisdictions outside the U.S., which we consider to be indefinitely reinvested. Accordingly, no U.S. federal and state income taxes and withholding taxes have been provided on these earnings. Our cash, cash-equivalents, short-term investments, and marketable securities held by our foreign subsidiaries totaled $31.5 million and $22.2 million as of December 31, 2014 and 2013. We do not intend, nor do we foresee a need, to repatriate these funds or other assets held outside the U.S. In the future, should we require more capital to fund discretionary activities in the U.S. than is generated by our domestic operations and is available through our borrowings, we could elect to repatriate cash or other assets from foreign jurisdictions that have previously been considered to be indefinitely reinvested.
Off-Balance Sheet Arrangements
We do not have guarantees or other off-balance sheet financing arrangements, including variable interest entities, which we believe could have a material impact on financial condition or liquidity.
Contractual Obligations
The following is a summary of our significant contractual obligations as of December 31, 2014:
 
(Dollars in millions)
Payments due by period
Contractual obligations
Total
 
Less than 1
year
 
1-3 years
 
4-5 years
 
After 5
years
Long-term debt (1)
$
742.3

 
$
22.7

 
$
45.4

 
$
45.4

 
$
628.8

Revolving credit facility (1)
35.1

 
0.5

 
0.5

 
34.1

 

Purchase obligations (2)
108.4

 
39.8

 
68.3

 
0.3

 

Operating leases (2)
290.5

 
57.5

 
93.6

 
65.4

 
74.0

Capital lease obligations (1)
46.1

 
7.3

 
12.5

 
8.2

 
18.1

Unrecognized tax benefits, net (3)
7.1

 

 

 

 

Other long-term liabilities (4)
86.3

 
2.9

 
4.1

 
4.5

 
74.8

Total contractual obligations
$
1,315.8

 
$
130.7

 
$
224.4

 
$
157.9

 
$
795.7

(1)
See Note 10 of Notes to Consolidated Financial Statements. Debt is assumed to be held to maturity with interest paid at the stated rate in effect at December 31, 2014.
(2)
See Note 18 of Notes to Consolidated Financial Statements.
(3)
We cannot reasonably estimate the timing of cash settlement for the liability associated with unrecognized tax benefits.
(4)
Other long-term liabilities include estimated minimum required payments for our unfunded retirement plan for certain officers. See Note 13 of Notes to Consolidated Financial Statements. Certain long-term liabilities, including deferred tax liabilities and post-retirement benefit obligations, are excluded as we cannot reasonably estimate the timing of payments for these items.
Critical Accounting Policies
Our consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of the financial statements requires us to make estimates and assumptions that affect the reported amounts and related disclosures. We continually evaluate the accounting policies and estimates used to prepare the financial statements.
Critical accounting policies are defined as those policies that relate to estimates that require us to make assumptions about matters that are highly uncertain at the time the estimate is made and could have a material impact on our results due to changes in the estimate or the use of different assumptions that could reasonably have been used. Our estimates are generally based on historical experience and various other assumptions that are judged to be reasonable in light of the relevant facts and circumstances. Because of the uncertainty inherent in such estimates, actual results may differ. We believe our critical accounting policies and estimates include allowances for losses on accounts and notes receivable, inventory valuation, accounting for goodwill and long-lived assets, self-insurance liabilities, supplier incentives, and business combinations.

23


Allowances for losses on accounts and notes receivable. We maintain valuation allowances based upon the expected collectability of accounts and notes receivable. The allowances include specific amounts for accounts that are likely to be uncollectible, such as customer bankruptcies and disputed amounts, and general allowances for accounts that may become uncollectible. These allowances are estimated based on a number of factors, including industry trends, current economic conditions, creditworthiness of customers, age of the receivables, changes in customer payment patterns, and historical experience. At December 31, 2014, accounts and notes receivable were $626.2 million, net of allowances of $13.3 million. An unexpected bankruptcy or other adverse change in the financial condition of a customer could result in increases in these allowances, which could have a material effect on the results of operations.
Inventory valuation. Merchandise inventories are valued at the lower of cost or market, with cost determined using the last-in, first-out (LIFO) method for Domestic segment inventories and the first-in, first-out (FIFO) method for International segment inventories. An actual valuation of inventory under the LIFO method is made only at the end of the year based on the inventory levels and costs at that time. LIFO calculations are required for interim reporting purposes and are based on estimates of the expected mix of products in year-end inventory. In addition, inventory valuation includes estimates of allowances for obsolescence and variances between actual inventory on-hand and perpetual inventory records that can arise throughout the year. These estimates are based on factors such as the age of inventory and historical trends. At December 31, 2014, the carrying value of inventory was $872.5 million, which is $116.2 million lower than the value of inventory had it all been accounted for on a FIFO basis.
Goodwill and long-lived assets. Goodwill represents the excess of consideration paid over the fair value of identifiable net assets acquired. Long-lived assets, which are a component of identifiable net assets, include intangible assets with finite useful lives, property and equipment, and computer software costs. Intangible assets with finite useful lives consist primarily of customer relationships and non-compete agreements acquired through business combinations. Certain assumptions and estimates are employed in determining the fair value of identifiable net assets acquired.
We evaluate goodwill for impairment annually and whenever events occur or changes in circumstance indicate that the carrying amount of goodwill may not be recoverable. In performing the impairment test, we perform qualitative assessments based on macroeconomic conditions, structural changes in the industry, estimated financial performance, and other relevant information. If necessary, we perform a quantitative analysis to estimate the fair value of the reporting unit using valuation techniques, including comparable multiples of the reporting unit's earnings before interest, taxes, depreciation and amortization (EBITDA) and discounted cash flows. The EBITDA multiples are based on an analysis of current enterprise valuations and recent acquisition prices of similar companies, if available. Goodwill totaled $423.3 million at December 31, 2014.
Long-lived assets, which exclude goodwill, are evaluated for impairment whenever events or changes in circumstances indicate that the carrying amount of long-lived assets may not be recoverable. We assess long-lived assets for potential impairment by comparing the carrying value of an asset, or group of related assets, to its estimated undiscounted future cash flows. At December 31, 2014, long-lived assets included property and equipment of $233.0 million, net of accumulated depreciation; intangible assets of $108.6 million, net of accumulated amortization; and computer software costs of $75.2 million, net of accumulated amortization.
We did not record any material impairment losses related to goodwill or long-lived assets in 2014. However, the impairment review of goodwill and long-lived assets requires the extensive use of accounting judgment, estimates and assumptions. The application of alternative assumptions could produce materially different results.
Self-insurance liabilities. We are self-insured for most employee healthcare, workers’ compensation and automobile liability costs; however, we maintain insurance for individual losses exceeding certain limits. Liabilities are estimated for healthcare costs using current and historical claims data. Liabilities for workers’ compensation and automobile liability claims are estimated using historical claims data and loss development factors. If the underlying facts and circumstances of existing claims change or historical trends are not indicative of future trends, then we may be required to record additional expense that could have a material effect on the results of operations. Self-insurance liabilities recorded in our consolidated balance sheets for employee healthcare, workers’ compensation and automobile liability costs totaled $13.0 million at December 31, 2014 and $13.9 million at December 31, 2013.
Supplier incentives. We have contractual arrangements with certain suppliers that provide incentives, including operational efficiency and performance-based incentives, on a monthly, quarterly or annual basis. These incentives are recognized as a reduction in cost of goods sold as targets become probable of achievement. Supplier incentives receivable are recorded for interim and annual reporting purposes and are based on our estimate of the amounts which are expected to be realized. If we do not achieve required targets under certain programs as estimated, it could have a material adverse effect on our results of operations.

24


Business Combinations. We allocate the fair value of purchase consideration to the tangible assets acquired, liabilities assumed and intangible assets acquired based on their estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. When determining the fair values of assets acquired and liabilities assumed, management makes significant estimates and assumptions, especially with respect to intangible assets.
Critical estimates in valuing certain intangible assets include but are not limited to future expected cash flows from customer relationships and discount rates. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates.

Recent Accounting Pronouncements
For a discussion of recent accounting pronouncements, see Note 1 of Notes to the Consolidated Financial Statements.
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
We are exposed to market risk from changes in interest rates related to our revolving credit facility. We had $33.7 million in outstanding borrowings and $5.0 million in letters of credit under the facility at December 31, 2014. A hypothetical increase in interest rates of 100 basis points would result in a potential reduction in future pre-tax earnings of approximately $0.1 million per year for every $10 million of outstanding borrowings under the revolving credit facility.
Due to the nature and pricing of our Domestic segment distribution services, we are exposed to potential volatility in fuel prices. Our strategies for helping to mitigate our exposure to changing domestic fuel prices have included entering into leases for trucks with improved fuel efficiency. We benchmark our domestic diesel fuel purchase prices against the U.S. Weekly Retail On-Highway Diesel Prices (benchmark) as quoted by the U.S. Energy Information Administration. The benchmark averaged $3.82 per gallon in 2014, decreased 2% from $3.92 per gallon in 2013. Based on our fuel consumption in 2014, we estimate that every 10 cents per gallon increase in the benchmark would reduce our Domestic segment operating earnings by approximately $0.3 million.
In the normal course of business, we are exposed to foreign currency translation and transaction risks. Our business transactions outside of the United States are primarily denominated in the Euro and British Pound. We may use foreign currency forwards, swaps and options, where possible, to manage our risk related to certain foreign currency fluctuations. However, we believe that our foreign currency transaction risks are low since our revenues and expenses are typically denominated in the same currency.
Item 8. Financial Statements and Supplementary Data
See Item 15. Exhibits and Financial Statement Schedules.
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
None.
Item 9A. Controls and Procedures
We carried out an evaluation, with the participation of management, including our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures (pursuant to Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report. Based upon that evaluation, the principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of December 31, 2014.
On October 1, 2014 and November 1, 2014, we completed our acquisitions of Medical Action and ArcRoyal, respectively. As permitted by the Securities and Exchange Commission under the current year acquisition scope exception, we have excluded these acquisitions from our 2014 assessment of the effectiveness of our internal control over financial reporting since it was not practicable for management to conduct an assessment of internal control over financial reporting between the acquisition date and the date of management’s assessment.
Except for the effect of the Medical Action and ArcRoyal acquisitions, there have been no change in our internal control over financial reporting during our last fiscal quarter (our fourth quarter in the case of an annual report) ended December 31, 2014, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

25


Item 9B. Other Information
On October 16, 2014, we redeemed all of our $200 million 6.35% senior notes due in 2016 (2016 Notes), which included the payment of a $17.4 million redemption premium. In connection with the redemption of the 2016 Notes, we terminated the Indenture dated April 7, 2006 under which the notes were issued.

26


Management’s Report on Internal Control over Financial Reporting
Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f), for Owens & Minor, Inc. (the company). Under the supervision and with the participation of management, including the company’s principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2014, based on the framework in Internal Control—Integrated Framework (1992) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
In reliance on guidance set forth in Question 3 of a “Frequently Asked Questions” interpretative release issued by the Staff of the SEC’s Office of the Chief Accountant and the Division of Corporation Finance in September 2004, as revised on September 24, 2007, regarding Securities Exchange Act Release No. 34-47986, Management’s Report on Internal Control Over Financial Reporting and Certification of Disclosure in Exchange Act Periodic Reports, management determined that it would exclude the Medical Action and ArcRoyal businesses, which were acquired on October 1, 2014 and November 1, 2014, respectively, from the scope of the assessment of the effectiveness of our internal control over financial reporting. The reason for this exclusion is that we acquired Medical Action and ArcRoyal in the fourth quarter of 2014 and it was not practical for management to conduct an assessment of internal control over financial reporting in the period between the dates the acquisitions were completed and the date of management’s assessment. Accordingly, management excluded Medical Action and ArcRoyal from its assessment of internal control over financial reporting. These acquisitions represent $340 million of total assets and $46.9 million of revenues as of and for the year ended December 31, 2014, of our consolidated financial statements. Medical Action and ArcRoyal will be included in management’s assessment of internal control over financial reporting for the year ending December 31, 2015.
Based on our evaluation under the COSO framework, management concluded that the company’s internal control over financial reporting was effective as of December 31, 2014.
The effectiveness of the company’s internal control over financial reporting as of December 31, 2014, has been audited by KPMG LLP, an independent registered public accounting firm, as stated in their report which is included in this annual report.
 



/s/ James L. Bierman
                                                                                        

James L. Bierman
President & Chief Executive Officer



/s/ Richard A. Meier
                                                                                       

Richard A. Meier
Executive Vice President & Chief Financial Officer

27


Report of Independent Registered Public Accounting Firm
The Board of Directors and Shareholders
Owens & Minor, Inc.:
We have audited Owens & Minor, Inc.’s internal control over financial reporting as of December 31, 2014, based on criteria established in Internal Control - Integrated Framework (1992) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Owens & Minor, Inc.’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit.
We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
In our opinion, Owens & Minor, Inc. maintained, in all material respects, effective internal control over financial reporting as of December 31, 2014, based on criteria established in Internal Control - Integrated Framework (1992) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
Owens & Minor, Inc. acquired Medical Action Industries, Inc. on October 1, 2014 and ArcRoyal on November 1, 2014, and management excluded from its assessment of the effectiveness of Owens & Minor, Inc.'s internal control over financial reporting as of December 31, 2014, Medical Action Industries, Inc.'s internal control over financial reporting associated with total assets of $269 million and total revenues of $40 million and ArcRoyal's internal control over financial reporting associated with total assets of $71 million and total revenues of $7 million included in the consolidated financial statements of Owens & Minor, Inc. as of and for the year ended December 31, 2014. Our audit of internal control over financial reporting of Owens & Minor, Inc. also excluded an evaluation of the internal control over financial reporting of Medical Action Industries, Inc. and ArcRoyal.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets of Owens & Minor, Inc. and subsidiaries as of December 31, 2014 and 2013, and the related consolidated statements of income, comprehensive income, changes in shareholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2014 and our report dated February 23, 2015, expressed an unqualified opinion on those consolidated financial statements.

/s/ KPMG LLP
Richmond, Virginia
February 23, 2015


28



Part III
Items 10-14.
Information required by Items 10-14 can be found at the end of the electronic filing of this Form 10-K and the registrant’s 2014 Proxy Statement pursuant to instructions (1) and G(3) of the General Instructions to Form 10-K.
Because our common stock is listed on the New York Stock Exchange (NYSE), our Chief Executive Officer is required to make, and he has made, an annual certification to the NYSE stating that he was not aware of any violation by of the corporate governance listing standards of the NYSE. Our Chief Executive Officer made his annual certification to that effect to the NYSE as of May 19, 2014. In addition, we have filed, as exhibits to this Annual Report on Form 10-K, the certifications of our principal executive officer and principal financial officer required under Sections 906 and 302 of the Sarbanes-Oxley Act of 2002 to be filed with the Securities and Exchange Commission regarding the quality of our public disclosure.






29


Part IV
Item 15. Exhibits and Financial Statement Schedules
a) The following documents are filed as part of this report:
b) Exhibits:
See Index to Exhibits on page 67.

30


OWENS & MINOR, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(in thousands, except per share data)
 
Year ended December 31,
2014
 
2013
 
2012
Net revenue
$
9,440,182

 
$
9,071,532

 
$
8,868,324

Cost of goods sold
8,270,216

 
7,954,457

 
7,943,670

Gross margin
1,169,966

 
1,117,075

 
924,654

Selling, general, and administrative expenses
926,977

 
863,656

 
682,595

Acquisition-related and exit and realignment charges
42,801

 
12,444

 
10,164

Depreciation and amortization
57,125

 
50,586

 
39,604

Other operating income, net
(16,473
)
 
(7,694
)
 
(4,462
)
Operating earnings
159,536

 
198,083

 
196,753

Loss on early retirement of debt
14,890

 

 

Interest expense, net
18,163

 
13,098

 
13,397

Income before income taxes
126,483

 
184,985

 
183,356

Income tax provision
59,980

 
74,103

 
74,353

Net income
$
66,503

 
$
110,882

 
$
109,003

 
 
 
 
 
 
Net income attributable to Owens & Minor, Inc. per common share:
 
 
 
 
 
Basic
$
1.06

 
$
1.76

 
$
1.72

Diluted
$
1.06

 
$
1.76

 
$
1.72

Cash dividends per common share
$
1.00

 
$
0.96

 
$
0.88

See accompanying notes to consolidated financial statements.

31


OWENS & MINOR, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(in thousands)
Year ended December 31,
2014
 
2013
 
2012
Net income
$
66,503

 
$
110,882

 
$
109,003

Other comprehensive income, net of tax:
 
 
 
 
 
Currency translation adjustments (net of income tax of $0 in 2014, $111 in 2013 and $210 in 2012)
(29,539
)
 
6,143

 
9,749

Change in unrecognized net periodic pension costs (net of income tax of $2,361 in 2014, $2,429 in 2013 and $1,671 in 2012)
(3,844
)
 
3,839

 
(2,611
)
Other (net of income tax of $72 in 2014, $32 in 2013 and $32 in 2012)
(186
)
 
(8
)
 
(50
)
Other comprehensive income (loss)
(33,569
)
 
9,974

 
7,088

Comprehensive income
$
32,934

 
$
120,856

 
$
116,091

See accompanying notes to consolidated financial statements.


32


OWENS & MINOR, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(in thousands, except per share data)
 
December 31,
2014
 
2013
Assets
 
 
 
Current assets
 
 
 
Cash and cash equivalents
$
56,772

 
$
101,905

Accounts and notes receivable, net
626,192

 
572,854

Merchandise inventories
872,457

 
771,663

Other current assets
315,285

 
279,510

Total current assets
1,870,706

 
1,725,932

Property and equipment, net
232,979

 
191,961

Goodwill, net
423,276

 
275,439

Intangible assets, net
108,593

 
40,406

Other assets, net
99,852

 
90,304

Total assets
$
2,735,406

 
$
2,324,042

Liabilities and equity
 
 
 
Current liabilities
 
 
 
Accounts payable
$
608,846

 
$
643,872

Accrued payroll and related liabilities
31,507

 
23,296

Deferred income taxes
37,979

 
41,613

Other current liabilities
326,223

 
281,427

Total current liabilities
1,004,555

 
990,208

Long-term debt, excluding current portion
608,551

 
212,786

Deferred income taxes
63,901

 
43,727

Other liabilities
67,561

 
52,278

Total liabilities
1,744,568

 
1,298,999

Commitments and contingencies

 

Equity
 
 
 
Owens & Minor, Inc. shareholders’ equity
 
 
 
Common stock, par value $2 per share; authorized—200,000 shares; issued and outstanding—63,070 shares and 63,096 shares
126,140

 
126,193

Paid-in capital
202,934

 
196,605

Retained earnings
685,765

 
691,547

Accumulated other comprehensive income (loss)
(24,001
)
 
9,568

Total Owens & Minor, Inc. shareholders’ equity
990,838

 
1,023,913

Noncontrolling interest

 
1,130

Total equity
990,838

 
1,025,043

Total liabilities and equity
$
2,735,406

 
$
2,324,042

See accompanying notes to consolidated financial statements.

33


OWENS & MINOR, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
Year ended December 31,
2014
 
2013
 
2012
Operating activities:
 
 
 
 
 
Net income
$
66,503

 
$
110,882

 
$
109,003

Adjustments to reconcile net income to cash provided by (used for) operating activities of continuing operations:
 
 
 
 
 
Depreciation and amortization
63,407

 
50,586

 
39,604

Share-based compensation expense
8,207

 
6,381

 
5,697

Deferred income tax (benefit) expense
(3,385
)
 
3,713

 
1,060

Provision for losses on accounts and notes receivable
448

 
787

 
1,004

Loss on early retirement of debt
14,890

 

 

Changes in operating assets and liabilities:
 
 
 
 
 
Accounts and notes receivable
(17,803
)
 
(38,645
)
 
27,161

Merchandise inventories
(57,329
)
 
(7,064
)
 
58,734

Accounts payable
(52,148
)
 
47,374

 
(18,694
)
Net change in other assets and liabilities
(25,828
)
 
(32,337
)
 
(4,490
)
Other, net
(723
)
 
(1,123
)
 
(573
)
Cash (used for) provided by operating activities
(3,761
)
 
140,554

 
218,506

Investing activities:
 
 
 
 
 
Acquisition, net of cash acquired
(248,536
)
 

 
(155,210
)
Additions to computer software and intangible assets
(22,384
)
 
(32,010
)
 
(29,131
)
Additions to property and equipment
(48,424
)
 
(28,119
)
 
(9,832
)
Proceeds from sale of property and equipment
156

 
3,051

 
3,298

Proceeds from investment sale
1,937

 

 

Cash used for investing activities
(317,251
)
 
(57,078
)
 
(190,875
)
Financing activities:
 
 
 
 
 
Proceeds from issuance of debt
547,693

 

 

Proceeds from revolver
33,700

 

 

Repayment of debt
(217,352
)
 

 

Cash dividends paid
(63,104
)
 
(60,731
)
 
(55,681
)
Repurchases of common stock
(9,934
)
 
(18,876
)
 
(15,000
)
Financing costs paid
(5,391
)
 

 
(1,303
)
Proceeds from exercise of stock options
1,180

 
5,352

 
4,986

Excess tax benefits related to share-based compensation
582

 
898

 
1,293

Purchase of noncontrolling interest
(1,500
)
 

 

Other, net
(7,314
)
 
(8,623
)
 
(2,710
)
Cash provided by (used for) financing activities
278,560

 
(81,980
)
 
(68,415
)
Effect of exchange rate changes on cash and cash equivalents
(2,681
)
 
2,521

 
2,734

Net increase (decrease) in cash and cash equivalents
(45,133
)
 
4,017

 
(38,050
)
Cash and cash equivalents at beginning of year
101,905

 
97,888

 
135,938

Cash and cash equivalents at end of year
$
56,772

 
$
101,905

 
$
97,888

See accompanying notes to consolidated financial statements.

34


OWENS & MINOR, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
(in thousands, except per share data)
 
 
Owens & Minor, Inc. Shareholders’ Equity
 
 
 
 
 
Common  Shares
Outstanding
 
Common Stock
($2 par value)
 
Paid-In
Capital
 
Retained
Earnings
 
Accumulated
Other
Comprehensive
Income (Loss)
 
Noncontrolling
Interest
 
Total Equity
Balance, December 31, 2011
63,449

 
$
126,900

 
$
179,052

 
$
619,629

 
$
(7,494
)
 
$
1,130

 
$
919,217

Net income
 
 
 
 
 
 
109,003

 
 
 
 
 
109,003

Other comprehensive income
 
 
 
 
 
 
 
 
7,088

 
 
 
7,088

Dividends declared ($0.88 per share)
 
 
 
 
 
 
(55,681
)
 
 
 
 
 
(55,681
)
Shares repurchased and retired
(522
)
 
(1,043
)
 
 
 
(13,957
)
 
 
 
 
 
(15,000
)
Share-based compensation expense, exercises and other
344

 
687

 
8,342

 
 
 
 
 
 
 
9,029

Balance, December 31, 2012
63,271

 
126,544

 
187,394

 
658,994

 
(406
)
 
1,130

 
973,656

Net income
 
 
 
 
 
 
110,882

 
 
 
 
 
110,882

Other comprehensive income
 
 
 
 
 
 
 
 
9,974

 
 
 
9,974

Dividends declared ($0.96 per share)
 
 
 
 
 
 
(60,573
)
 
 
 
 
 
(60,573
)
Shares repurchased and retired
(560
)
 
(1,120
)
 
 
 
(17,756
)
 
 
 
 
 
(18,876
)
Share-based compensation expense, exercises and other
385

 
769

 
9,211

 
 
 
 
 
 
 
9,980

Balance, December 31, 2013
63,096

 
126,193

 
196,605

 
691,547

 
9,568

 
1,130

 
1,025,043

Net income
 
 
 
 
 
 
66,503

 
 
 
 
 
66,503

Other comprehensive loss
 
 
 
 
 
 
 
 
(33,569
)
 
 
 
(33,569
)
Dividends declared ($1.00 per share)
 
 
 
 
 
 
(62,934
)
 
 
 
 
 
(62,934
)
Shares repurchased and retired
(291
)
 
(583
)
 
 
 
(9,351
)
 
 
 
 
 
(9,934
)
Share-based compensation expense, exercises and other
265

 
530

 
7,024

 
 
 
 
 
 
 
7,554

Purchase of noncontrolling interest
 
 
 
 
(695
)
 
 
 
 
 
(1,130
)
 
(1,825
)
Balance, December 31, 2014
63,070

 
$
126,140

 
$
202,934

 
$
685,765

 
$
(24,001
)
 
$

 
$
990,838

See accompanying notes to consolidated financial statements.

35


OWENS & MINOR, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(in thousands, unless otherwise indicated)
Note 1—Summary of Significant Accounting Policies
Owens & Minor, Inc. and subsidiaries (we, us or our), is a Fortune 500 company headquartered in Richmond, Virginia. We are a leading healthcare logistics company that connects the world of medical products to the point of care by providing vital supply chain assistance to the providers of healthcare services and the manufacturers of healthcare products, supplies, and devices in the United States and Europe. We serve our customers with a service portfolio that covers procurement, inventory management, delivery and sourcing for the healthcare market. With fully developed networks in the United States and Europe, we are equipped to serve a customer base ranging from hospitals, integrated healthcare systems, group purchasing organizations, and the U.S. federal government, to manufacturers of life-science and medical devices and supplies, including pharmaceuticals in Europe.
Our Domestic segment includes all functions in the United States relating to our role as a healthcare logistics company providing distribution, packaging and logistics services to healthcare providers and manufacturers. The International segment consists of our European third-party logistics and packaging businesses.
Basis of Presentation. The consolidated financial statements include the accounts of Owens & Minor, Inc. and the subsidiaries it controls, in conformity with U.S generally accepted accounting principles (GAAP). During 2014, we purchased the remaining outside stockholder's interest in a consolidated subsidiary that was partially owned. Therefore we do not present a noncontrolling interest as a component of equity as of December 31, 2014. All significant intercompany accounts and transactions have been eliminated.
Reclassifications. Certain prior year amounts have been reclassified to conform to current year presentation.
Use of Estimates. The preparation of the consolidated financial statements in conformity with GAAP requires us to make assumptions and estimates that affect reported amounts and related disclosures. Estimates are used for, but are not limited to, the allowances for losses on accounts and notes receivable, inventory valuation allowances, supplier incentives, depreciation and amortization, goodwill valuation, valuation of intangible assets and other long-lived assets, valuation of property held for sale, self-insurance liabilities, tax liabilities, defined benefit obligations, share-based compensation and other contingencies. Actual results may differ from these estimates.
Cash and Cash Equivalents. Cash and cash equivalents includes cash and marketable securities with an original maturity or maturity at acquisition of three months or less. Cash and cash equivalents are stated at cost. Nearly all of our cash and cash equivalents are held in cash depository accounts in major banks in the United States and Europe.
Book overdrafts represent the amount of outstanding checks issued in excess of related bank balances and are included in accounts payable in our consolidated balance sheets, as they are similar to trade payables and are not subject to finance charges or interest. Changes in book overdrafts are classified as operating activities in our consolidated statements of cash flows.
Accounts and Notes Receivable, Net. Accounts receivable from customers are recorded at the invoiced amount. We assess finance charges on overdue accounts receivable that are recognized as other operating income based on their estimated ultimate collectability. We have arrangements with certain customers under which they make deposits on account. Customer deposits in excess of outstanding receivable balances are classified as other current liabilities.
We maintain valuation allowances based upon the expected collectability of accounts and notes receivable. Our allowances include specific amounts for accounts that are likely to be uncollectible, such as customer bankruptcies and disputed amounts and general allowances for accounts that may become uncollectible. Allowances are estimated based on a number of factors, including industry trends, current economic conditions, creditworthiness of customers, age of the receivables, changes in customer payment patterns, and historical experience. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.

Financing Receivables and Payables. We have an order-to-cash program in our International segment under which we invoice manufacturers’ customers and remit collected amounts to the manufacturers. We retain credit risk for certain uncollected receivables under this program where contractually obligated. We continually monitor the expected collectability in this program and maintain valuation allowances when it is likely that an amount may be or may become uncollectible. Allowances are estimated based on a number of factors including creditworthiness of customers, age of the receivables and

36


historical experience. We write off uncollected receivables under this program when collection is no longer being pursued. At December 31, 2014 and 2013, the allowance for uncollectible accounts as part of this program was $0.4 million and $0.1 million. Fees charged for this program are included in net revenue. Product pricing and related product risks are retained by the manufacturer. Balances receivable and related amounts payable under this program are classified in other current assets and other current liabilities in the consolidated balance sheets.
Merchandise Inventories. Merchandise inventories are valued at the lower of cost or market, with cost determined by the last-in, first-out (LIFO) method for Domestic segment inventories. Cost of International segment inventories is determined using the first-in, first out (FIFO) method.
Property and Equipment. Property and equipment are stated at cost less accumulated depreciation or, if acquired under capital leases, at the lower of the present value of minimum lease payments or fair market value at the inception of the lease less accumulated amortization. Depreciation and amortization expense for financial reporting purposes is computed on a straight-line method over the estimated useful lives of the assets or, for capital leases and leasehold improvements, over the term of the lease, if shorter. In general, the estimated useful lives for computing depreciation and amortization are four to 15 years for warehouse equipment, five to 40 years for buildings and building improvements, and three to eight years for computers, furniture and fixtures, and office and other equipment. Straight-line and accelerated methods of depreciation are used for income tax purposes. Normal maintenance and repairs are expensed as incurred, and renovations and betterments are capitalized.
Leases. We have entered into non-cancelable agreements to lease most of our office and warehouse facilities with remaining terms generally ranging from one to fifteen years. We also lease most of our transportation and material handling equipment for terms generally ranging from three to ten years. Certain information technology assets embedded in an outsourcing agreement are accounted for as capital leases. Leases are classified as operating leases or capital leases at their inception. Rent expense for leases with rent holidays or pre-determined rent increases are recognized on a straight-line basis over the lease term. Incentives and allowances for leasehold improvements are deferred and recognized as a reduction of rent expense over the lease term.
Goodwill. We evaluate goodwill for impairment annually and whenever events occur or changes in circumstance indicate that the carrying amount of goodwill may not be recoverable. In 2014 we changed the date of our annual goodwill impairment test from April 30 to October 1 to better align the timing of our analysis with the annual planning and budgeting process. We review goodwill first by performing a qualitative assessment to determine if it is more likely than not that the fair value of a reporting unit exceeds its carrying value. If not, we then perform a quantitative assessment by first comparing the carrying amount to the fair value of the reporting unit. If the fair value of the reporting unit is determined to be less than its carrying value, a second step is performed to measure the goodwill impairment loss as the excess of the carrying value of the reporting unit’s goodwill over the estimated fair value of its goodwill. We estimate the fair value of the reporting unit using valuation techniques which can include comparable multiples of the unit’s earnings before interest, taxes, depreciation and amortization (EBITDA) and present value of expected cash flows. The EBITDA multiples are based on an analysis of current enterprise values and recent acquisition prices of similar companies, if available.
Intangible Assets. Intangible assets acquired through purchases or business combinations are stated at fair value at the acquisition date and net of accumulated amortization in the consolidated balance sheets. Intangible assets, consisting primarily of customer relationships, customer contracts, non-competition agreements, trademarks, and tradenames are amortized over their estimated useful lives. In determining the useful life of an intangible asset, we consider our historical experience in renewing or extending similar arrangements. Customer relationships are generally amortized over 10 to 15 years and other intangible assets are amortized generally for periods between one and 15 years, based on their pattern of economic benefit or on a straight-line basis.
Computer Software. We develop and purchase software for internal use. Software development costs incurred during the application development stage are capitalized. Once the software has been installed and tested, and is ready for use, additional costs incurred in connection with the software are expensed as incurred. Capitalized computer software costs are amortized over the estimated useful life of the software, usually between three and ten years. Computer software costs are included in other assets, net, in the consolidated balance sheets. Unamortized software at December 31, 2014 and 2013 was $75.2 million and $74.4 million. Depreciation and amortization expense includes $16.4 million, $14.2 million and $11.0 million of software amortization for the years ended December 31, 2014, 2013 and 2012. Additional amortization of $6.0 million related to the accelerated amortization of an information system which is being replaced in the International segment is included in acquisition-related and exit and realignment charges in the 2014 consolidated statement of income.

37


Long-Lived Assets. Long-lived assets, which include property and equipment, finite-lived intangible assets, and unamortized software costs, are evaluated for impairment whenever events or changes in circumstances indicate that the carrying amount of long-lived assets may not be recoverable. We assess long-lived assets for potential impairment by comparing the carrying value of an asset, or group of related assets, to their estimated undiscounted future cash flows.
Self-Insurance Liabilities. We are self-insured for most employee healthcare, workers’ compensation and automobile liability costs; however, we maintain insurance for individual losses exceeding certain limits. Liabilities are estimated for healthcare costs using current and historical claims data. Liabilities for workers’ compensation and automobile liability claims are estimated using historical claims data and loss development factors. If the underlying facts and circumstances of existing claims change or historical trends are not indicative of future trends, then we may be required to record additional expense or reductions to expense. Self-insurance liabilities are included in other accrued liabilities on the consolidated balance sheets.
Revenue Recognition. Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price or fee is fixed or determinable, and collectability is reasonably assured. Under most of our distribution contracts, we record revenue at the time shipment is completed as title passes to the customer when the product is received by the customer.
Revenue for activity-based fees and other services is recognized as work is performed and as amounts are earned. Depending on the specific contractual provisions and nature of the deliverable, revenue from services may be recognized on a straight-line basis over the term of the service, on a proportional performance model, based on level of effort, or when final deliverables have been provided. Additionally, we generate fees from arrangements that include performance targets related to cost-saving initiatives for customers that result from our supply-chain management services. Achievement against performance targets, measured in accordance with contractual terms, may result in additional fees paid to us or, if performance targets are not achieved, we may be obligated to refund or reduce a portion of our fees or to provide credits toward future purchases by the customer. For these arrangements, all contingent revenue is deferred and recognized as the performance target is achieved and the applicable contingency is released. When we determine that a loss is probable under a contract, the estimated loss is accrued.
We allocate revenue for arrangements with multiple deliverables meeting the criteria for a separate unit of accounting using the relative selling price method and recognize revenue for each deliverable in accordance with applicable revenue recognition criteria.
In most cases, we record revenue gross, as we are the primary obligor in our sales arrangements, bear the risk of general and physical inventory loss and carry all credit risk associated with sales. When we act as an agent in a sales arrangement and do not bear a significant portion of these risks, primarily for our third-party logistics business, we record revenue net of product cost. Sales taxes collected from customers and remitted to governmental authorities are excluded from revenues.
Cost of goods sold. Cost of goods sold includes the cost of the product (net of supplier incentives and cash discounts) and all costs incurred for shipments of products from manufacturers to our distribution centers for all customer arrangements where we are the primary obligor, bear the risk of general and physical inventory loss and carry all credit risk associated with sales. We have contractual arrangements with certain suppliers that provide incentives, including cash discounts for prompt payment, operational efficiency and performance-based incentives. These incentives are recognized as a reduction in cost of goods sold as targets become probable of achievement.
In situations where we act as an agent in a sales arrangement and do not bear a significant portion of these risks, primarily for our third-party logistics business, there is no cost of goods sold and all costs to provide the service to the customer are recorded in SG&A.
As a result of different practices of categorizing costs and different business models throughout our industry, our gross margins may not necessarily be comparable to other distribution companies.
Selling, General and Administrative (SG&A) Expenses. SG&A expenses include shipping and handling costs, labor and other costs for selling and administrative functions associated with our distribution and logistics services and all costs associated with our fee-for-service arrangements.
Shipping and Handling. Shipping and handling costs are included in SG&A expenses on the consolidated statements of income and include costs to store, move, and prepare products for shipment, as well as costs to deliver products to customers. Shipping and handling costs totaled $576.8 million, $528.2 million and $372.5 million for the years ended

38


December 31, 2014, 2013 and 2012, respectively. Third-party shipping and handling costs billed to customers, which are included in net revenue, are immaterial for all periods presented.
Share-Based Compensation. We account for share-based payments to employees at fair value and recognize the related expense in selling, general and administrative expenses over the service period for awards expected to vest.
Derivative Financial Instruments. We are directly and indirectly affected by changes in certain market conditions, which may adversely impact our financial performance and are referred to as “market risks.” When deemed appropriate, we use derivatives as a risk management tool to mitigate the potential impact of certain market risks, primarily foreign currency exchange risk. We use forward contracts, which are agreements to buy or sell a quantity of a commodity at a predetermined future date, and at a predetermined rate or price. We do not enter into derivative financial instruments for trading purposes. All derivatives are carried at fair value in our consolidated balance sheets, which is determined by using observable market inputs (Level 2). The cash flow impact of the our derivative instruments is primarily included in our consolidated statements of cash flows in net cash provided by operating activities.
Income Taxes. We account for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income from continuing operations in the period that includes the enactment date. Valuation allowances are provided if it is more likely than not that a deferred tax asset will not be realized. When we have claimed tax benefits that may be challenged by a tax authority, an estimate of the effect of these uncertain tax positions is recorded. It is our policy to provide for uncertain tax positions and the related interest and penalties based upon an assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. To the extent that the tax outcome of these uncertain tax positions changes, based on our assessment, such changes in estimate may impact the income tax provision in the period in which such determination is made.
We earn a portion of our operating earnings in foreign jurisdictions outside the United States, which we consider to be indefinitely reinvested. Accordingly, no United States federal and state income taxes and withholding taxes have been provided on these earnings. Our cash, cash-equivalents, short-term investments, and marketable securities held by our foreign subsidiaries totaled $31.5 million and $22.2 million as of December 31, 2014 and 2013. We do not intend, nor do we foresee a need, to repatriate these funds or other assets held outside the U.S. In the future, should we require more capital to fund discretionary activities in the U.S. than is generated by our domestic operations and is available through our borrowings, we could elect to repatriate cash or other assets from foreign jurisdictions that have previously been considered to be indefinitely reinvested. Upon distribution of these assets, we could be subject to additional U.S. federal and state income taxes and withholding taxes payable to foreign jurisdictions, where applicable.
Fair Value Measurements. Fair value is determined based on assumptions that a market participant would use in pricing an asset or liability. The assumptions used are in accordance with a three-tier hierarchy, defined by GAAP, that draws a distinction between market participant assumptions based on (i) observable inputs such as quoted prices in active markets (Level 1), (ii) inputs other than quoted prices in active markets that are observable either directly or indirectly (Level 2) and (iii) unobservable inputs that require the use of present value and other valuation techniques in the determination of fair value (Level 3).
The carrying amounts of cash and cash equivalents, accounts receivable and accounts payable reported in the consolidated balance sheets approximate fair value due to the short-term nature of these instruments. Property held for sale is reported at estimated fair value less selling costs with fair value determined based on recent sales prices for comparable properties in similar locations (Level 2). The fair value of long-term debt is estimated based on quoted market prices or dealer quotes for the identical liability when traded as an asset in an active market (Level 1) or, if quoted market prices or dealer quotes are not available, on the borrowing rates currently available for loans with similar terms, credit ratings, and average remaining maturities (Level 2). See Notes 7, 10 and 11 for the fair value of property held for sale, debt instruments and derivatives.
Acquisition-Related and Exit and Realignment Charges. We present costs incurred in connection with acquisitions in acquisition-related and exit and realignment charges in our consolidated statements of income. Acquisition-related charges consist primarily of transaction costs incurred to perform due diligence and to analyze, negotiate and consummate an acquisition, costs to perform post-closing activities to establish the organizational structure, and costs to transition the acquired company’s information technology and other operations and administrative functions from the former owner.

39


Costs associated with exit and realignment activities are recorded at their fair value when incurred. Liabilities are established at the cease-use date for remaining operating lease and other contractual obligations, net of estimated sub-lease income. The net lease termination cost is discounted using a credit-adjusted risk-free rate of interest. We evaluate these assumptions quarterly and adjust the liability accordingly. The current portion of accrued lease and other contractual termination costs is included in other accrued liabilities on the consolidated balance sheets, and the non-current portion is included in other liabilities. Severance benefits are recorded when payment is considered probable and reasonably estimable.
Income Per Share. Basic and diluted income per share are calculated pursuant to the two-class method, under which unvested share-based payment awards containing nonforfeitable rights to dividends are participating securities.
Foreign Currency Translation. Our foreign subsidiaries generally consider their local currency to be their functional currency. Assets and liabilities of these foreign subsidiaries are translated into U.S. dollars at period-end exchange rates and revenues and expenses are translated at average exchange rates during the period. Cumulative currency translation adjustments are included in accumulated other comprehensive income (loss) in shareholders’ equity. Gains and losses on intercompany foreign currency transactions that are long-term in nature and which we do not intend to settle in the foreseeable future are also recognized in other comprehensive income (loss) in shareholders’ equity. Realized gains and losses from foreign currency transactions are recorded in other operating income, net in the consolidated statements of income and were not material to our consolidated results of operations in 2014, 2013, and 2012.
Business Combinations. We account for acquired businesses using the acquisition method of accounting, which requires that the assets acquired and liabilities assumed be recorded at the date of acquisition at their respective fair values. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.
Recent Accounting Pronouncements. During 2014, we adopted Accounting Standard Updates (ASU’s) issued by the Financial Accounting Standards Board (FASB).

We adopted an Accounting Standard Update (ASU) issued by the Financial Accounting Standards Board (FASB) for presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The adoption of this guidance did not have an impact on our financial position or results of operations.

On May 28, 2014, the FASB issued an ASU, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective on January 1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. We are evaluating the effect that the ASU will have on our consolidated financial statements and related disclosures. We have not yet selected a transition method nor have we determined the effect of the standard on our ongoing financial reporting.

40


Note 2—Significant Risks and Uncertainties
Many of our hospital customers in the U.S. are represented by group purchasing organizations (GPOs) that contract with us for services on behalf of the GPO members. GPOs representing a significant portion of our business are Novation, LLC (Novation), MedAssets Inc. (MedAssets) and Premier, Inc. (Premier). Members of these GPOs have incentives to purchase from their primary selected distributor; however, they operate independently and are free to negotiate directly with distributors and manufacturers. For 2014, 2013 and 2012, net revenue from hospitals under contract with these GPOs represented the following approximate percentages of our net revenue annually: Novation—33%; MedAssets (including Broadlane in 2012)—24% to 25%; and Premier—21% to 24%.
Net revenue from sales of product supplied by subsidiaries of Covidien Ltd. and Johnson & Johnson Healthcare Systems, Inc. represented between approximately 13% to 14% and 9% to 10% of our net revenue annually for 2014, 2013 and 2012, respectively.
Note 3—Acquisitions
On October 1, 2014, we completed the acquisition of Medical Action Industries Inc., (Medical Action), a leading producer of surgical kits and procedure trays, which will enable an expansion of our capabilities in the assembly of kits, packs and trays for the healthcare market.
On November 1, 2014, we acquired ArcRoyal, a privately held surgical kitting company based in Ireland (ArcRoyal). The transaction expanded our capabilities in the assembly of kits, packs and trays in the European healthcare market.
The combined consideration for these two acquisitions was $261.6 million, net of cash acquired, and including debt assumed of $13.4 million (capitalized lease obligations). The acquisitions did not have a material effect on operational results for 2014.
The purchase price was allocated to the underlying assets acquired and liabilities assumed based upon our preliminary estimate of their fair values at the date of acquisition, with certain exceptions permitted under GAAP. The combined purchase price exceeded the preliminary estimated fair value of the net tangible and identifiable intangible assets by $150.5 million, which was allocated to goodwill. The following table presents, in the aggregate, the preliminary estimated fair value of the assets acquired and liabilities assumed recognized as of the acquisition date. The allocation of purchase price to assets and liabilities acquired is not yet complete.
 
Preliminary Fair
Value Estimated as of
Acquisition Date
 
Assets acquired:
 
 
Current assets
$
90,608

 
Property and equipment
34,048

 
Goodwill
150,492

 
Intangible assets
77,623

 
Total assets
352,771

 
Liabilities assumed:
 
 
Current liabilities
64,736

 
Noncurrent liabilities
26,426

 
Total liabilities
91,162

 
Fair value of net assets acquired, net of cash
$
261,609

 
We are amortizing the fair value of acquired intangible assets, primarily customer relationships, over their remaining weighted average useful lives of 14 years.
Goodwill of $150.5 million consists largely of expected opportunities to expand our kitting capabilities. We assigned goodwill of $21.9 million to our International segment and $128.6 million to our Domestic segment. None of the goodwill recognized is expected to be deductible for income tax purposes.

41


Pro forma results of operations for these acquisitions have not been presented because the effects on revenue and net income were not material to our historic consolidated financial statements.
Acquisition-related expenses in the current year consisted primarily of transaction costs incurred to perform due diligence and to analyze, negotiate and consummate the Medical Action and ArcRoyal acquisitions, and costs to begin the integration of the acquired operations (including certain severance and contractual payments to former management). We also incurred certain acquisition-related charges in 2014 associated with costs in Movianto to resolve certain issues and claims with the former owner. We recognized pre-tax acquisition-related expenses of $16.1 million in 2014 related to these activities.
Acquisition-related expenses of $3.5 million and $10.5 million for the years ended December 31, 2013 and 2012 were all related to Movianto which included $8.0 million in transaction costs in 2012 and the remainder in both years was related to transition and integration activities.
Note 4—Accounts and Notes Receivable, Net
Allowances for losses on accounts and notes receivable of $13.3 million, $15.0 million and $14.7 million have been applied as reductions of accounts receivable at December 31, 2014, 2013, and 2012. Write-offs of accounts and notes receivable were $3.1 million, $1.1 million and $1.9 million for 2014, 2013 and 2012.
Note 5—Merchandise Inventories
At December 31, 2014 and 2013, we had inventory of $872.5 million and $771.7 million, of which $811.3 million and $749.4 million were valued under LIFO. If LIFO inventories had been valued on a current cost or first-in, first-out (FIFO) basis, they would have been greater by $116.2 million and $108.6 million as of December 31, 2014 and 2013. At December 31, 2014, included in our inventory was $20.0 million in raw materials, $5.4 million in work in process and the remainder was finished goods. At December 31, 2013, all of our inventory was finished goods.
Note 6—Financing Receivables and Payables
At December 31, 2014 and 2013, we had financing receivables of $196.2 million and $198.5 million and related payables of $168.8 million and $165.3 million outstanding under our order-to-cash program, which were included in other current assets and other current liabilities, respectively, in the consolidated balance sheets.
Note 7—Property and Equipment
Property and equipment consists of the following:
December 31,
2014
 
2013
Warehouse equipment
$
169,083

 
$
160,379

Computer equipment
31,162

 
31,784

Building and improvements
87,974

 
50,225

Leasehold improvements
58,046

 
49,879

Land and improvements
17,771

 
17,489

Furniture and fixtures
12,539

 
11,491

Office equipment and other
19,781

 
8,240

 
396,356

 
329,487

Accumulated depreciation
(163,377
)
 
(137,526
)
Property and equipment, net
$
232,979

 
$
191,961

Depreciation expense for property and equipment was $35.5 million, $33.1 million and $26.1 million for the years ended December 31, 2014, 2013, and 2012. The gross value of assets recorded under capital leases was $40.0 million and $20.6 million with associated accumulated depreciation of$10.5 million and $8.7 million as of December 31, 2014 and 2013, respectively.
Property held for sale in our Domestic segment was $5.6 million at December 31, 2014 and is included in other current assets, net, in the consolidated balance sheet. We are actively marketing the property for sale; however, the ultimate timing is dependent on local market conditions. We had no property classified as held for sale at December 31, 2013.

42


Note 8—Goodwill and Intangible Assets
The following table summarizes the changes in the carrying amount of goodwill through December 31, 2014:
 
Domestic Segment
 
International Segment
 
Consolidated Total
Carrying amount of goodwill, December 31, 2013
$
248,498

 
$
26,941

 
$
275,439

Currency translation adjustments

 
(2,655
)
 
(2,655
)
Acquisitions (See Note 3)
128,591

 
21,901

 
150,492

Carrying amount of goodwill, December 31, 2014
$
377,089

 
$
46,187

 
$
423,276

Intangible assets at December 31, 2014 and 2013 were as follows:
 
2014
 
2013
 
Customer
Relationships
 
Other
Intangibles
 
Customer
Relationships
 
Other
Intangibles
Gross intangible assets
$
125,448

 
$
3,405

 
$
51,544

 
$
3,933

Accumulated amortization
(19,773
)
 
(487
)
 
(14,281
)
 
(790
)
Net intangible assets
$
105,675

 
$
2,918

 
$
37,263

 
$
3,143

Weighted average useful life
14 years

 
6 years

 
13 years

 
6 years

Customer relationships increased $77.6 million on a gross basis in 2014 as a result of the Medical Action and ArcRoyal acquisitions. At December 31, 2014, $66.1 million in net intangible assets were held in the Domestic segment and $42.5 million were held in the International segment. Amortization expense for intangible assets was $5.5 million for 2014, $3.3 million for 2013 and $2.5 million for 2012.
Based on the current carrying value of intangible assets subject to amortization, estimated amortization expense is $10.5 million for 2015, $10.4 million for 2016, $10.3 million for 2017, $9.6 million for 2018 and $9.4 million for 2019.
Note 9—Exit and Realignment Costs

We periodically incur exit and realignment and other charges associated with optimizing our operations which include the closure and consolidation of certain distribution and logistics centers, administrative offices and warehouses in the United States and Europe. These charges also include costs associated with our strategic organizational realignment which include management changes, certain professional fees, and costs to streamline administrative functions and processes.

Exit and realignment charges by segment for the years ended December 31, 2014, 2013, and 2012 were as follows:
Year ended December 31,
2014
 
2013
 
2012
Domestic segment
$
7,223

 
$
8,176

 
$
(366
)
International segment
19,490

 
751

 

Total exit and realignment charges
$
26,713

 
$
8,927

 
$
(366
)
The following table summarizes the activity related to exit and realignment cost accruals through December 31, 2014:

43


 
Lease
obligations
 
Severance and
Other
 
Total
Accrued exit and realignment charges, January 1, 2012
$
8,264

 
$
1,831

 
$
10,095

Provision for exit and realignment activities
95

 
1,088

 
1,183

Change in estimate
(2,183
)
 

 
(2,183
)
Interest accretion
267

 

 
267

Cash payments, net of sublease income
(1,345
)
 
(1,803
)
 
(3,148
)
Accrued exit and realignment charges, December 31, 2012
5,098

 
1,116

 
6,214

Provision for exit and realignment activities
2,932

 
128

 
3,060

Cash payments, net of sublease income
(5,596
)
 
(769
)
 
(6,365
)
Accrued exit and realignment charges, December 31, 2013
2,434

 
475

 
2,909

Provision for exit and realignment activities
5,592

 
6,338

 
11,930

Change in estimate
(1,260
)
 

 
(1,260
)
Cash payments, net of sublease income
(3,191
)
 
(3,926
)
 
(7,117
)
Accrued exit and realignment charges, December 31, 2014
$
3,575